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Neuron development involves intricate morphological changes reliant on 
the serine/threonine kinase mammalian target of rapamycin complex 1 (mTORC1), 
a cell growth regulator that supports anabolic processes such as mRNA 
translation. Upregulated mTORC1 activity during neuron development causes 
altered neuron morphology, which is a hallmark of neurodevelopmental disorders 
such as Tuberous Sclerosis Complex (TSC). While the role of mTORC1 in neuron 
development is well documented, there is insufficient information on what precise 
upstream and downstream components of the mTOR pathway are involved.  
Two underexplored regulators of neuron development are the unc-51 like 
autophagy activating kinase 1 (Ulk1) and solute carrier family 7 member 5 
(Slc7a5). Ulk1 is a pro-autophagic kinase and direct substrate of mTORC1. 
Autophagy is important to general cell maintenance and is linked to synaptic 
refinement via dendritic spine pruning. Ulk1 non-canonical functions involve Golgi-
Endoplasmic Reticulum trafficking, which is also vital for neuron development and 
function. Slc7a5 is an amino acid transporter and upstream driver of mTORC1 
activity by signaling the mTOR complex to the lysosomal surface for activation 
when amino acids are present.   
Herein, the role of mTORC1, Slc7a5, and Ulk1 is explored in mouse neuron 
development, and we apply this insight to develop and propagate a neural stem 
cell conditional Tsc2 knockout mouse colony. We demonstrate through genetic 
manipulation that Ulk1 and Slc7a5 play a role in neuron development in vivo. 
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Overexpression of Ulk1 in developing cortical neurons resulted in decreased 
dendrite complexity. Increased Ulk1 Serine 757 phosphorylation in Ulk1 
overexpressing neurons was associated with dendrite complexity closer to control 
levels. Thus, mTORC1 mediated Ulk1 Serine 757 phosphorylation is likely required 
during neuron development to control Ulk1 activity.   
 Slc7a5 knockdown was detrimental to olfactory bulb granule cell 
development, specifically at later stages between Postnatal day 14-30. This is a 
time of synaptic integration and continued growth of dendrites in granule cells. 
Slc7a5 also regulates mTORC1 activity in granule cells during development. 
Knockdown of Slc7a5 decreased mTORC1 activity as indicated by Ribosomal S6 
phosphorylation. Decreased dendrite complexity following Slc7a5 knockdown was 
partially rescued by Ras homolog enriched in brain (Rheb) overexpression, which 
drives mTORC1 activity.  
Finally, we documented defects in a Tsc2 transgenic mouse model and 
documented developmental defects in Tsc2 null granule cells including dendrite 
hypertrophy and increased soma size.  Taken together, the presented research 
demonstrates how neuron development is tightly regulated, with implications for 
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The purpose of the studies presented here are to gain novel insight into 
regulators of canonical neuron development using genetic in vivo manipulations 
and applying this insight into the development of a Tuberous Sclerosis Complex 2 
(Tsc2) mouse model. Undercovering the inner workings of the nervous system is 
an arduous task that has only intensified with advances in technology. Humans 
owe the evolution of the brain to our success as a species (1,2). On an individual 
level, proper brain functionality allows for intricate levels of communication and 
collaboration.  
The importance of the brain means that proper development is critical to 
quality of life. Many different aspects of brain development can go wrong and result 
in debilitating neurological conditions such as epilepsy and intellectual disabilities. 
This highlights the complexity of brain development and function, which is 
dependent on the orchestration and fine-tuned interactions of many different cells.  
The brain is made up of many different cell types, each being critical to 
overall brain functionality. These cell types include neurons, astrocytes, microglia, 
and oligodendrocytes. Additionally, each cell type falls under many different 
subtypes. Each cell type has a unique critical role, but the true workhorse of the 
brain directly responsible for brain function are neurons. Neurons form the network 
in which the brain can carry out its function. This network is reliant on processes 
called dendrites and axons that grow during development and form connections 
with other neurons called synapses (3). Depending on the type of neuron, a 
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chemical messenger called a neurotransmitter is released at one neuron 
(presynaptic neuron) and exerts either an excitatory or inhibitory effect on the 
receiving neuron (postsynaptic neuron) (3). Neurons can be connected to over 
10,000 other neurons, and the sum of the receiving signals will cause a neuron to 
fire an action potential if the neuron passes a depolarization threshold (4). Action 
potentials are the mechanism in which neurons communicate within the neural 
network (4). 
 Action potentials rely on ion gradients, where the neuron’s membrane 
potential is negative at rest. A stimulus, such as the excitatory neurotransmitter 
glutamate, is released by a presynaptic neuron and causes a flux of positive ions 
into the postsynaptic neuron (4). If the membrane potential crosses a certain 
threshold, the neuron will fire its own action potential in the form of a wave of 
positive ions that travel down the axon (or dendrite in some cases). The action 
potential invades and depolarizes the neuron’s presynaptic terminal, which results 
in the release of neurotransmitters that influences the activation of other neurons 
(5). These neurotransmitters are released and bind to receptors located on post 
synaptic neuron dendritic spines (5). Many neurodevelopmental disorders are 
caused by defective neuron development. Neurological defects can result from 
issues such as altered neuron morphology, signaling changes, and ectopic 
migration (6,7). For this reason, the continued investigation of neuron development 
is paramount to address patient needs.   
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Overview of Cortical Neuron Development. 
Cortical neurogenesis involves arguably the most precise and intricate cell 
migration events in the body (2). Neural stem cells (NSCs) in the ventricular zone 
(VZ) comprise a neurogenetic niche that give rise to radial glial cells which further 
produce cortical progenitors or postmitotic neurons that then migrate and form the 
six layers of the cerebral cortex in an inside out position specific fashion, such that 
deeper layer cells are older than the cells that make up the more superficial layers 
(8–12). Cell migration is guided by glial shafts that provide a scaffold (13).  
Following arrival to the terminal position, the cells mature into various types 
of neurons. The cerebral cortex contains a vast amount of cellular heterogeneity, 
with many classification schemes existing to classify neurons (14–16). One type is 
the pyramidal neuron, which is the most abundant type in the cerebral cortex. 
Pyramidal neurons have a soma, two dendrite domains, and a projecting axon that 
extends to the ipsilateral or contralateral hemisphere (17–19). The two dendrite 
domains are the apical dendrite, which extends toward the pial surface, and basal 
dendrites that form more local connections. For example, basal dendrites of layer 
II/III pyramidal neurons in mice typically do not extend past layer II/III, but can reach 
layer IV when the neuron is situated in deeper regions of layer III (18). During 
neuron development both dendrite types undergo extensive outgrowth and form 
connections via synapses that integrate the neuron into the cortical network (20–
22).  
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 Neuron to neuron communication is a highly specialized process, with 
neurons typically forming thousands of synapses with other neurons. Pyramidal 
neurons are excitatory and receive glutamatergic input from their dendrites by 
other pyramidal neurons while being kept in check via local GABAergic inhibitory 
interneuron connections usually formed at the soma and axon (19,21). The 
synaptic input field of neurons is thus in part determined by the localization of the 
dendrites (21). Due to the postmitotic nature of pyramidal neurons in the cortex, 
particularly in regard to higher functioning organisms such as humans, proper 
morphogenesis during development is critical for proper neuron integration and 
subsequent function (6,23–28). Dendrite structure has influence on neuron activity 
including firing properties (24). Additionally, the size of the dendrite arbor has a 
direct effect on the axon initial segment action potential onset (25). Consistent with 
the premise that correct dendritic architecture is required for proper function, 
patients with various neurological disorders exhibit atypical dendrite formation 
(6,26–28).  
 
Morphological changes in developing cortical neurons. 
To demonstrate neuron morphological changes, plasmids encoding Green 
fluorescent Protein (GFP) were introduced into NSCs of embryonic day (e) 14.5 
mice by in utero electroporation (IUE) (Fig. 1.1A). IUE involves injecting plasmid 
DNA into the lateral ventricle of a developing mouse embryo and applying an 
electrical field using electrodes. By changing the directionality of the electrodes, 
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selective targeting various regions of the cortex including the somatosensory 
cortex (SSC) or the anterior cingulate cortex (ACC) could be achieved (Fig. 1.1B). 
Neurons began to extend small basal cellular processes protruding from a small 
elliptical soma by Postnatal day (P) 0, at which point the morphology of neurons in 
the ACC and SSC were similar (Fig. 1.1E,F).  
Cortical neuron dendrite complexity was assessed at P0 and P21 after 
e14.5 IUE of CAG-GFP. The dendrite complexity at P21 was observed to be 
significantly increased proximal to the soma (10–100 μm), having on average a 
range of 2.5625 to 6.0 crossings compared to 0.0689 to 1.8275 crossings 
(P<0.0001) (Fig. 1.1C-E). On average, SSC neurons had 1.3 basal dendrites at 
P0, but this increased to 4.6 basal dendrites by P21 (P<0.0001) (Fig. 1.1C). These 

















Figure 1.1 Morphological changes in developing cortical neurons. A. 
Schematic diagram of in utero electroporation. B. Electroporated 
cerebral cortex outlined (upper) and schematic of electrode 
directionality in relation to plasmid injection. C. Sholl analysis of P0 
(black) and P21 (green) neurons in the somatosensory cortex (P0 
N=29; P21 N=16). D. Quantification of the number of basal dendrites 
in P0 and P21 neurons (P0 N=38; P21 N=34).  E. Representative 
image of GFP positive neurons at P0 and P21 in the ACC. F. 
Representative image of GFP positive neurons at P0 and P21 in the 
SSC. Scale bar=50 μm. ACC=Anterior Cingulate Cortex, 
SSC=Somatosensory Cortex. ****=P<0.0001. 
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mTOR activity in developing cortical neurons in vivo. 
A major regulator of dendrite morphology in neurons is the serine threonine 
kinase mammalian target of rapamycin complex 1 (mTORC1), which acts as an 
anabolic growth regulator by promoting protein synthesis and translation in the 
presence of amino acids and growth factors (20,29,30). mTORC1 is one of two 
mTOR complexes, with mTORC2 being the second. mTORC1 controls cell growth 
by phosphorylating p70S6 kinase (p70S6K) and 4EBP (31–33). p70S6K 
subsequently phosphorylates the ribosomal S6 subunit (S6) (33–36). mTORC1 is 
activated by the GTPase Ras homolog enriched in brain (Rheb) and is inhibited by 
the GTPase activating protein complex encoded for by TSC1/2 (37,38). The mTOR 
complexes are required for proper brain development (39,40). Knocking out mTOR 
in NSCs reduces NSC proliferation and cortical thickness (39). Mutations in the 
mTOR pathway cause epilepsy, intellectual delay, and neuropsychiatric co-
morbidities (41). Increased mTORC1 activity accelerates axon growth, increases 
dendrite arborization, prevents autophagic pruning and leads to hyper-connectivity 
(20,30,42,43). Thus, mTORC1 levels must be carefully titrated during neuron 
development. The stringent regulation of mTOR activity and protein translation 
during neurogenesis was recently highlighted in a previous study that examined 
the role of mTOR activity in mouse NSC differentiation (44). Another study also 
found changes in mTORC1 activity in human embryonic NSCs during 
differentiation into neurons in vitro (45).  
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To confirm the presence of mTOR, we performed immunohistochemical 
analysis of coronal e14.5-16.5 brain sections for the phosphorylated form of S6 
(Ser240/244), an established indirect downstream mTOR substrate. pS6 staining 
at e14-16.5 was predominantly localized to DCX positive neuroblasts and enriched 
in neuroblasts within the outer layers of the cortical plate (Fig. 1.2A,B). pS6 
positive neuroblasts were also occasionally found in the ventricular zone (Fig. 
1.2C). Levels of pS6 remained elevated at P0 in cortical neurons labeled with GFP 
following e14.5 in utero electroporations (Fig. 1.2D-F). pS6 could be detected in 
the ACC at P21, as well as in electroporated neurons in the SSC (Fig. 1.2G,H,I). 









Figure 1.2 mTOR activity in developing cortical neurons in vivo. A. Coronal 
section of e16 brain stained for pS6 (red), DCX (green), Topro-3 (blue). Scale 
bar=150 μm. B. Cortical plate demonstrating pS6 (red) cells are DCX (green) 
positive neuroblasts (Scale bar=50 μm). C. Image of ventricular zone 
demonstrating that most pS6 (red) positive cells are DCX positive (green) 
neuroblasts (Scale bar=50 μm). D. Coronal section of e14.5 electroporated 
brain at P0 showing GFP positive cells (Scale bar=100 μm). E. P0 coronal 
section shown in E showing pS6 (Scale bar=100 μm). F. Merge of GFP (green), 
pS6 (red), and Topro-3 (blue) showing co-localization of mTOR activity in 
neurons (Scale bar=100 μm). G. Coronal section of P21 brain showing pS6 
staining in ACC (Scale bar=50 μm). H. 5× image of G from P21 brain showing 
GFP (green) and pS6 (red) in ACC (Scale bar=150 μm). I. Coronal section of 
P21 brain showing GFP (green), pS6 (red), and Topro-3 (blue) in SSC (Scale 
bar=50 μm). ACC=Anterior Cingulate Cortex, SSC=Somatosensory Cortex. 
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Effect of perturbed mTOR activity during neuron development. 
Effects on neuron morphology and dendrite complexity are phenocopied by 
expression of constitutively active Rheb or Tsc1 knockout (30,42,46). Abnormal 
dendrite patterning caused by mTOR hyper-activation is seen in focal cortical 
dysplasia (FCD) and TSC models (30,42,47–49). Ectopic expression of 
constitutively active or wild-type Rheb model FCDs. To the effect of perturbed 
mTOR activity on neuron development, we performed IUE of wild-type Rheb. 
Soma size was examined at P14 in control and Rheb expressing neurons. Rheb 
expressing neurons had significantly larger and more complex dendrite arbors in 
the ACC and SSC (Fig. 1.3A,B). Ectopic cells were found in lower layers of the 
cortex (Fig. 1.3C,D).  Moreover, Rheb overexpression significantly increased 
soma size (Fig. 1.3E).  The misplaced cells in combination with an increased size 
and hypertrophic dendritic arbors gave the appearance of a focal cortical 



















Figure 1.3 Effect of perturbed mTOR activity during cortical neuron 
development. A. Sholl analysis of control and Rheb ACC neurons at P14. 
B. Sholl analysis of control and Rheb SSC neurons at P14. C. 
Representative image of P14 control electroporated SSC neurons. D. 
Representative image of P14 Rheb electroporated SSC neuron. 
Quantification of SSC soma size. F. P14 Rheb electroporated neurons. 
Scale bar=50 μm. ACC=Anterior Cingulate Cortex, SSC=Somatosensory 
Cortex. *=P<0.05. ****=P<0.0001. 
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Methods 
In utero electroporation 
In utero electroporation was performed by aseptic survival surgery on 
embryonic day (e) 15.5-16 pregnant CD1 mice. Pregnant mice (e12) were acquired 
from Charles Rivers laboratory and allowed to acclimate to cages for 3 days which 
corresponds to an age of e15. Following acclimation, cages were placed into a 
biological safety cabinet (BSC). Mice were assessed for signs of health. Weight, 
approximate age, sex, and strain will be documented prior to surgery. 
Documentation of grooming and physical activity and body temperature were 
assessed. Mice were injected with 10 mg/kg buprenorphine 30 minutes prior to 
anesthetization. Following intraperitoneal injection of analgesic, mice were 
transported for surgery into a BSC. Mice were placed into an anesthesia induction 
chamber and 3% isofluorane was applied. Following appropriate anesthetization, 
mice were placed onto a pre-disinfected surgical table with a heat source and 
attached to a nose cone with 2-3% isoflurane flow. Mice were shaved with #40 
blade clippers and the skin prepared for aseptic surgery using triplicate, alternating 
washes of chlorhexidine and sterile water. A midline ventral laparotomy was 
performed. Uterine horns were slowly and carefully removed with ringed forceps 
and a scoopula.   
DNA solution (~1-1.5 μg/μl) diluted with PBS with 0.1% fast green was 
made prior to surgery. DNA solution (0.5–1.0 μl) was injected into the lateral 
ventricle using a pulled glass pipette. Glass pipettes were pulled with a P97 Sutter 
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micropipette puller with the settings: Heat, 580; Pull, 20; Velocity, 40; Time, 100. 
Pulled pipettes were irradiated in a sterile hood with UV light. DNA injection, 
electrodes (model 520; BTX) were soaked in 0.9% saline solution and placed on 
the heads of the embryos, and five, 30-volt square pulses of 50 ms duration with 
950-ms intervals were applied using a pulse generator (ECM830; BTX).  A 
combination of plasmids encoding GFP, tomato, or Rheb under the chicken β-actin 
promoter with CMV enhancer (CAG) was electroporated. After injection and 
electroporation, abdominal muscles were closed with 5-6,1 cm absorbable sutures 
(needle 5-0 C-1 (taper) 3/8 13 mm and skin closed with 3-5 9 mm autoclips. Mice 
were subject to heightened monitoring of health and signs of deterioration for the 
following two days. The date of birth of pups was recorded and mice sacrificed at 
indicated time points.   
 
Sholl analysis and cell size 
Images of the anterior cingulate cortex and the somatosensory cortex were 
uploaded to Fiji (ImageJ 1.51r/n). Dendrites were traced using the Simple Neurite 
Tracer plug-in. The marking tool was used to trace the projections from the soma 
to the projection terminus. Sholl analysis was performed at 10 μm intervals to a 
maximum radius of 400 μm to quantify dendritic arborization using the Fiji Sholl 
plug-in. The longest dendrite was selected as the primary apical dendrite and 
length calculated by simple neurite tracer. Basal dendrites were quantified by 
Simple Neurite Tracer as dendrites localized to the bottom two thirds of the soma. 
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To measure cell size, Z-stack images of GFP+ cells coronal sections were 
acquired with a ×20 dry objective (Numerical Aperture, 0.75) using high-low 
settings to minimize saturation. In Image J, the freehand tracing tool was used to 
outline cell somas. Cell size was represented relative to the indicated controls. 
 
Slice preparation and immunohistochemistry 
Mice were deeply anesthetized where appropriate with pentobarbital (50 
mg/kg) or on ice (P0 pups) and decapitated. The brain was removed in PBS and 
placed in 4% paraformaldehyde in PBS and incubated for 4 hours at room 
temperature (e12-P0) or overnight at 4°C, then washed in PBS. The region of 
electroporation was imaged using a Nikon AZ100. The next day, 300-μm-thick 
slices were prepared using a vibratome (Leica VTS 1000). Immunostaining was 
performed in free-floating 300-μm-thick slices. Free-floating sections were blocked 
in PBS containing 0.1% Triton X-100, 0.1% Tween-20, and 2% BSA and incubated 
in primary antibodies (see below) overnight at 4°C. After three washes in PBS 
containing 0.1% Tween-20, slices were incubated with the appropriate secondary 
antibody (Alexa Fluor series at 1:500 [Invitrogen]) for 1 hour at room temperature 
or overnight at 4 degrees C. Primary antibodies were goat anti-DCX (1:500; Santa 
Cruz Biotechnology Inc.) and rabbit anti-pS6 (1:1,000; Cell Signaling; Ser240/244, 
61H9, #4838). Each staining was replicated in at least 3-5 different mice. Z-section 
images were acquired on a spectral confocal microscope (Leica SPE) with a ×20 
dry objective (N.A. 0.75) or ×63 oil immersion objective (N.A. 1.5). Low-
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magnification images were acquired with a ×5 dry objective. Images were analyzed 
and reconstructed using ImageJ 1.51r software or Photoshop CS6. 
 
Hypothesis 
Taken together, mTORC1 is required for neuron development. In addition, 
mTORC1 activity is dynamic and carefully titrated during neurodevelopment 
(44,45). While the role of mTORC1 is to support anabolic growth during this 
developmental window, mTORC1 activity fluctuation also means that upstream 
mTORC1 regulators and downstream substrates likely require precise regulation 
for proper development to occur. Thus, alterations in components of the mTOR 
pathway could prove detrimental to neuron development. 
 One downstream candidate of mTORC1 is Unc-51 like autophagy 
activating kinase 1 (Ulk1), a pro-autophagic kinase that is inhibited by mTORC1 
via Ulk1 phosphorylation at Serine 757 (Ser757). Ulk1 may be a valuable target 
for therapeutic intervention in neurodevelopmental disorders stemming from 
upregulated mTOR activity. TSC studies have shown altered autophagy activity 
that may be the result of mTORC1 dependent inhibition of Ulk1 (43).  
An upstream candidate is the solute carrier family 7 member 5 (Slc7a5), a 
neutral amino acid transporter that regulates mTORC1 activity by shuttling certain 
amino acids including leucine (50–52). Slc7a5 inactivation is a cause of autism 
spectrum disorder and leads to neurodevelopmental defects in mouse models 
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embryonically (53,54). An upregulation of SLC7A5 was detected in TSC patient 
balloon cells (55). Additionally, Slc7a5 regulates Kv1.2 channels in vitro (56). 
 Herein, we propose to define the role of Slc7a5 and Ulk1 in mouse neuron 
development through in vivo techniques. We will then apply this insight into 
developing a NSC conditional transgenic Tsc2 knockout mouse colony that can be 
used as a model to study aberrant neuron development. Based on the clear role 
of the mTOR pathway in neuron development, I propose that two components of 
the mTOR pathway, Ulk1 and Slc7a5, are involved with regulating neuron 
development. Additionally, using a conditional NSC specific Tsc2 knockout mouse 
model would provide valuable insight into neuron development and defects 














Role of Ulk1 kinase in cortical neuron development 
Abstract 
The cerebral cortex development process involves vast amounts of cell 
growth and increases in dendrite complexity by cortical neurons. The anabolic 
growth regulator mammalian target of rapamycin complex one (mTORC1) has a 
well-established role in these morphological changes. Due to the importance of 
mTORC1 in development, it is likely that other components of the mTORC1 
pathway play a role in development. One mTORC1 substrate, Ulk1, is a pro-
autophagic kinase that is also involved in Golgi-ER transport and is inhibited by 
mTORC1 via phosphorylation at Ulk1 Serine 757 (Ser757). Loss-of-function 
studies have demonstrated that Ulk1 is required for proper neuron development 
and maturation in mice. However, gain-of-function approaches have not 
addressed whether ectopic Ulk1 expression is sufficient to disrupt neuron 
development, and what role mTORC1 has in Ulk1 regulation during this period of 
growth. Here mTORC1 activity, Ulk1, and Ulk1 inhibitory phosphorylation at 
Ser757 were confirmed to be present in developing pyramidal neurons undergoing 
dendrite outgrowth in the cortex. A CAG-Ulk1 plasmid was constructed and 
introduced into NSCs of the ventricular zone by IUE. Migration was unaltered, but 
neuron dendrite arborization was decreased by P14 compared to controls. 
Moreover, a notable divergence in Ulk1 overexpressed neurons manifested, with 
a subset developing with relatively normal morphology. Ulk1 overexpression was 
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found to induce elevated inhibitory Ulk1 Ser757 phosphorylation in a subset of 
developing neurons and this expression was associated with improved dendrite 
arborization compared to neurons with low pUlk1 Ser757 expression. We propose 
that mTORC1 regulates Ulk1 activity in developing neurons, with ectopic Ulk1 





































As described in chapter I, a major regulator of dendrite morphology in 
neurons is the serine threonine kinase mTORC1, which acts as an anabolic growth 
regulator by promoting protein synthesis and translation in the presence of amino 
acids and growth factors (20,29,30). For this reason, we speculate that the 
downstream substrate of mTORC1, Ulk1, requires equally stringent regulation for 
proper development to occur (57–59). 
Unc.51 was identified in a mutational screen in C. elegans (60). Unc.51 
mutations caused paralysis and uncoordinated motor activity due to abnormal 
motor neuron development (60,61). Notably, alterations in Unc.51 led to defective 
axon growth, premature termination, and mislocalization (62,63). The homolog of 
Unc.51, Ulk1, is likewise expressed within mammalian neurons where the 
introduction of a dominant negative form inhibits neurite outgrowth (64). Both Ulk1 
and the homolog Ulk2 were found to localize to sensory neuron axon growth cones 
(65). RNAi of Ulk1 in mammalian sensory neurons caused spurious axon 
arborization and prevented axon growth (65). As further evidence that Ulk1 
regulates neuron morphology, Ulk1/2 double knockout forebrains have defects in 
all major cortical axonal tracts including the corpus callosum and anterior 
commissure (66).   
The fact that Ulk1/2 inhibition causes developmental defects is surprising 
because Ulk1 is an established pro-autophagic protein. Typically, metabolic stress 
activates Ulk1 which subsequently phosphorylates Beclin1 and VPS34 (67). An 
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example of a metabolic stress is that glucose starvation activates AMP Kinase-
dependent Ulk1 phosphorylation and autophagy (68). AMP Kinase (AMPK) 
phosphorylates Ulk1 at serine 555, 317, and 777 (68–70). However, AMPK is 
inactive during neuronal maturation and is dispensable for cortical development 
(71). Interestingly, AMPK activation during development prevents axon and 
dendrite outgrowth (71,72). This is likely caused by AMPK activation of TSC2, 
which in turn inhibits mTORC1. In addition, AICAR treated neurons activates 
AMPK and AKT (72). Although AMPK is inactive during neuronal maturation, loss 
of Ulk1/2 causes neuronal degeneration (73). It is unclear to what extent this is 
due to abnormal autophagy. For example, autophagy gene knockouts do not 
phenocopy Ulk1/2 axon defects (66). Moreover, Ulk1/2 double-knockouts do not 
have autophagy defects (66,73). Therefore, alternative roles for Ulk1/2 in the brain 
are likely. For example, Ulk1/2 phosphorylation of SEC16 regulates ER to Golgi 
trafficking in neurons (73).  
To investigate the role of Ulk1 in neuron development, herein experiments 
are presented that examine the state of Ulk1 and mTORC1 in developing mouse 




Experiments were approved by the Clemson University Institutional Animal 
Care and Use Committee. Experiments were performed according to guidelines 
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set forth by the Clemson University Institutional Animal Care and Use Committee 
and NIH Guide for the Care and Use of Laboratory Animals. For primary cell culture 
experiments and neonatal electroporation, pregnant CD-1 mice were obtained 
from Charles River Laboratories. Mice were housed under pathogen-free 
conditions with a 12-hr light/dark cycle.  
 
In utero electroporation 
Performed as described in chapter I using a combination of plasmids 
encoding GFP under the chicken β-actin promoter with CMV enhancer (CAG), or 
CAG-Ulk1 plasmids. 
  
Neuro-2A cell culture and transfection 
Neuro-2a mouse neuroblastoma cells (American Type Culture Collection 
CCL-131) were grown in tissue culture-treated polystyrene multi-well plates or 
flasks (Falcon; BD Biosciences Discovery Labware) in a 5% CO2 37°C incubator. 
Neuro-2a cells were routinely propagated and DNA transfections were performed 
with PolyJet (SignaGen Laboratories). Initially 4 x 105 cells were seeded into 6 well 
plates or 2 x 105 cells into 12 well plates 24 hours prior to transfection. 72 μl Polyjet 
was mixed with 1.2 ml DMEM and then 600 μl of this solution was added to test 
tubes containing 6 μg of DNA in 600 μl DMEM. After ten minutes, 200 μl of 
polyjet/DNA solution was added to each well for a final concentration of 1 μg of 
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tdTomato (Addgene # 83029) or CAG-Ulk1 per well. For starvation experiments, 
cells were put in DMEM lacking Fetal Bovine Serum. 
 
Sholl, colocalization, and cell size analysis 
Images were uploaded to Fiji (ImageJ 1.52e) and using the Simple Neurite 
Tracer plug-in, dendrites were traced from the soma to the projection terminus. 
Sholl analysis was performed at 10 μm intervals to quantify dendritic arborization 
using the Sholl plug-in.  
The freehand tracing tool in Fiji allowed for quantification of cell size by 
measuring cell soma area using 20x dry objective Z-stack images (Numerical 
Aperture, 0.75) of GFP+ cells in coronally sliced brains. 
The cell counter tool using combined channels along with the channels tool 
allowed for quantification of the number of cells that were both GFP and pS6 
positive and thus colocalized. 
 
Slice preparation and immunohistochemistry 
Performed as described in Chapter I using rabbit anti-pUlk1 757 (1:500; Cell 
Signaling Technology; D7O6U, #14202), rabbit anti-Ulk1 (1:500; Cell Signaling 
Technology; D8H5, #8054), rabbit anti-pS6 (1:500; Cell Signaling Technology; 




Primary neuron culture 
Pregnant e16.5 mice were anesthetized, uterine horn removed and placed 
on ice. Embryos were removed and brains were dissected into chilled DMEM 
(Invitrogen). Cortices were extracted and placed into 12 mL of chilled DMEM in a 
15 mL conical tube. Following dissection of embryos, cortical tissue was 
transferred into a TI75 flask containing DMEM with 50 micromolar dAPV, 10 U/mL 
papain, and 0.25 mg/mL L-cysteine. Following a 15-minute incubation at 37°C, 
dissociated tissue was next transferred to a 15 mL conical tube and gently 
triturated with fire polished glass pipettes. Following a 300 x g spin for 5 minutes, 
the supernatant was decanted and pellet resuspended in warm Neurobasal Plus 
(Invitrogen) complete media (2% B27 plus, 1X Glutamax, 50 ng/mL BDNF, 50 
ng/mL IGF1, and 50 μM dAPV). Cells were counted using a hemocytometer and 
plated at 1 x 105 on poly-D-lysine coated wells containing coverslips. The next day, 
half the media was replaced with fresh media, and this was repeated every 3 days. 
Experiments were performed 7 days later.  
 
Pharmacological Treatments 
Neurons were treated with the indicated amounts of Rapamycin (#9904s, Cell 
Signaling Technology) or Torin1 (#14379, Cell Signaling Technology). Torin1 was 
re-constituted in DMSO (MP Biomedicals) for a 1mM stock. Rapamycin was re-
constituted in DMSO for a 100 mM stock. Eqi-molar DMSO was used for all 
conditions. Cultured neurons were treated for 2 hours. Western blot samples were 
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collected in 2% SDS in RIPA buffer containing protease and phosphatase inhibitor 
cocktail. Lysates were briefly sonicated on ice and centrifuged at 13,200 rpm for 
10 minutes in a tabletop Eppendorf 5414 centrifuge. Proteins were resolved by 
standard electrophoresis conditions on 12% polyacrylamide precast mini-Protean 
TGX gels and transferred to polyvinylidene difluoride (PVDF) membranes. 
Membranes were rinsed in TBST (Tris-buffered saline, 0.1% Tween 20) for 5 
minutes at room temperature and subsequently blocked in 5% w/v nonfat milk in 
TBST for 1 hour at room temperature. Samples were incubated overnight at 4°C 
with the following antibodies: rabbit anti-pS6 (1:1,000; Cell Signaling Technology; 
Ser240/244, 61H9, #4838), rabbit anti-total S6 ribosomal protein (1:1,000; Cell 
Signaling Technology; 5G10, #2217), rabbit anti-pUlk1 757 (1:1,000; Cell 
Signaling Technology; D7O6U, #14202), rabbit anti-pBeclin1 15 (1:1000; Cell 
Signaling Technology; D4B7R, #84966), rabbit anti-total Beclin1 (1:1000; Cell 
Signaling Technology; D4B7R, #84966), and rabbit anti-total Ulk1 (1:1000; Cell 
Signaling Technology; D8H5, #8054). Following an additional five rinses each of 
10 minutes in TBST, samples were incubated for 1 hour at room temperature with 
donkey or goat anti-rabbit antibodies in blocking buffer and then subjected to four 
15-minute washes in TBST and visualized using enhanced chemiluminescence 
with film. All phospho-antibody/total antibody ratios were quantified using the same 
PVDF membrane. PVDF membranes were briefly stripped for 5-15 minutes at 
room temperature using Restore Western Blot Stripping Buffer (#21059, Thermo 
Fisher Scientific) before re-probing for total levels of that protein. Films were 
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scanned as tiff files at 600 dpi in color format with an HP Officejet Pro 8600 scanner 
and subjected to densitometric analysis. 
 
Phosphatase experiments  
Neuro-2a cells were transfected and lysate collected for western blot as 
described above. Following transfer, the PVDF membrane was cut in half so both 
contained six lanes each (3 control and 3 Ulk1). One of these halves was subjected 
to Lambda protein phosphatase (Sigma-Aldrich; P9614) treatment for four hours, 
followed by an alkaline phosphatase (Sigma-Aldrich; P0114) treatment for 30 more 
minutes. Blots were then washed, blocked, and probed as described above.   
 
Statistics 
Data were analyzed with Prism (Version 8; GraphPad). Statistical 
significance was determined by Student’s T-test (Colocalization analysis, # of 
crossings, cell size, western blots), One way ANOVA (Western blots with >3 
conditions) with multiple comparisons test, or two-way ANOVA with Tukey’s 








Late stage developing cortical neurons undergo morphological changes. 
To begin, we performed IUE into the LV at age e15.5 to allow visualization 
of neurons with GFP (Fig. 2.1A,B). To ascertain the state of the labeled neurons, 
morphological changes between P14 and P30 were quantified. While soma size 
did not change, dendrite complexity significantly increased from P14 to P30 







Figure 2.1 Late stage developing cortical neurons undergo 
morphological changes. A. Morphology of P14 GFP electroporated 
neurons in the SSC following IUE. B. Morphology of P30 electroporated 
neurons in the SSC following IUE. C. Soma Size analysis of P14 and 
P30 neurons in the SSC (P14 N=3, n=69; P30 N=5, n=113). D. Sholl 
analysis of P14 and P30 neurons in the SSC (P14 N=3, n=39; P30 N=3, 
n=28). SSC=Somatosensory cortex. IUE=In utero electroporation. 




mTORC1 activity is present in the developing cortex. 
Immunohistochemistry (IHC) at P14 and P30 confirmed pS6 Ser240/244 is 
present in cortical neurons, and thus mTORC1 is active (Fig. 2.2A-D). 
Interestingly, the number of GFP positive neurons that colocalized with pS6 
decreased from ~40% to ~10% between P14 and P30, indicating that as neurons 
complete development mTOR activity is reduced (P<0.001) (Fig. 2.2E). Finally, to 
confirm the pS6 staining labeled mature neurons, slices were co-stained with 
NeuN and pS6 (Fig. 2.2F,G). Taken together, between P14 and P30 mTORC1 
activity is correlated with continued dendrite outgrowth but not increasing soma 





Figure 2.2 mTORC1 activity is present in the developing cortex. A,B. 
PS6 immunohistochemistry on P14 SSC after GFP IUE. C,D. PS6 
immunohistochemistry on P30 SSC after GFP IUE.  E. GFP and pS6 
colocalization analysis P14 versus P30 (P14 N=8; P30 N=6).  F,G. NeuN 
and pS6 immunohistochemistry at P21. SSC=Somatosensory Cortex. 




Ulk1 is present in cortical neurons and phosphorylated by mTORC1 at Ser757. 
 
IHC confirmed the presence of both Ulk1 and Ulk1 inhibitory 
phosphorylation at Ser757 in developing cortical neurons in vivo (Fig. 2.3A,B). 
Additionally, Ulk1 and pUlk1 Ser757 were detected in cortical lysate from P14 to 
P30 (Fig. 2.3C). Since pUlk1 Ser757 and pS6 were found in cortical neurons 
during development, in vitro pharmacological experiments using the mTOR 
inhibitors Torin1 and rapamycin were performed to confirm the relationship 
between mTOR and Ulk1 (Fig. 2.3D). Torin1 significantly reduced pUlk1 Ser757 
levels in primary cultured neurons (P<0.05), with rapamycin reducing levels to a 
























Figure 2.3 Ulk1 is present in cortical neurons and phosphorylated by 
mTORC1 at Ser757. A. Ulk1 IHC from P14 control cortex.  B. NeuN and 
pUlk1 757 IHC from P7 cortex. C. Representative western blots of pUlk1 
Ser757, Ulk1, and Akt in dissected cortical tissue lysate at indicated 
timepoints (N=6,6,6). D. Western blots of pUlk1 Ser757, Ulk1, and Akt 
following equimolar DMSO,100 nM rapamycin, or 100 nM Torin1 treatment 





Ectopic Ulk1 is phosphorylated at Ser757 and Ser555 in vitro. 
Ulk1 was transfected into Neuro-2a cells to test the hypothesis that 
increased Ulk1 leads to increased Ulk1 activity. Ulk1 expression under a CAG 
promoter was significantly enhanced (P<0.0001), but phosphorylation of the Ulk1 
substrate Beclin1 was not increased (Fig. 2.4A,B). Beclin1 phosphorylation, 
however, was increased by starvation (P<0.05) (Fig. 2.4A,B). Since Ulk1 activity 
was not increased by Ulk1 expression, we measured Ulk1 Ser555 stimulatory 
phosphorylation. pUlk1 Ser555 was markedly increased in Ulk1 transfected Neuro-
2a cells (P<0.001) (Fig. 2.4C,D). This eliminated the possibility that a lack of 
Ser555 phosphorylation prevented full Ulk1 activation. Another potential 
mechanism that prevents Ulk1 activity is mTOR dependent inhibitory Ulk1 Ser757 
phosphorylation. We therefore quantified Ulk1 Ser757 phosphorylation and found 


















Figure 2.4 Ectopic Ulk1 is phosphorylated at Ser757 and Ser555 in vitro. A. 
Quantification of Ulk1/GAPDH and pBeclin1/Beclin1 in GFP control or Ulk1 
transfected Neuro-2a cells (N=3,3,3,3). Cells were cultured in complete 
media or starved. B. Representative western blots from A. C. Quantification 
of pUlk1 Ser757/GAPDH and pUlk1 Ser555/GAPDH in GFP control or Ulk1 
transfected Neuro-2a cells (N=3,3,3,3). Cells were cultured in complete 





Specificity of phospho-Ulk1 antibodies 
Given the extraordinarily robust stimulation of Ulk1 phosphorylation, 
phospho-antibody cross-reactivity to total Ulk1 was a concern. However, 
phosphatase treatment eliminated pUlk1 Ser757 (P<0.0001) and pUlk1 Ser555 
expression (P<0.0001) (Fig. 2.5A-C,I). To begin to explore the role of Ulk1 in 
neuron development, e15 cortical neurons were electroporated with Ulk1 and GFP, 
removed 24 hours later, and cultured for 7 days in vitro (DIV) (Fig. 2.5D-H). Ulk1 
electroporated neurons had an approximate 3-fold increase in pUlk1 Ser757 and 
no detectable change in pUlk1 Ser555 in comparison to control neurons (Fig. 2.5E-
H). These results demonstrate that ectopic Ulk1 expression increases pUlk1 

























Ectopic Ulk1 expression leads to defective neuron development. 
 
Next, IUE with Ulk1 and GFP were performed in mice, with brains collected 
at P14 and labeled neurons examined for any defects. Sholl analysis revealed that 
a large percentage of Ulk1 overexpressed neurons had decreased dendrite 
complexity (Fig. 2.6A-C,F). Interestingly, when the total number of crossings were 
visualized in a percent frequency diagram it was observed that a subset of Ulk1 
overexpressed neurons had dendrite complexity within the range of control 
Figure 2.5 Specificity of phospho-Ulk1 antibodies. A,B. Western blots of pUlk1 
Ser757, pUlk1 Ser555, and total Ulk1 from GFP control or Ulk1 transfected 
Neuro-2a cells with or without phosphatase treatment. C. Quantification of 
pUlk1 Ser757 in A (N=3,3,3,3). D. Primary neuron cultures at 7 DIV. E-H. Ulk1 
and GFP electroporated neurons (green) stained for pUlk1 Ser757 (E, F) or 
pUlk1 Ser555 (G, H). I. Quantification of pUlk1 Ser555 in B (N=3,3,3,3). 




neurons (Fig.2.6C). We next sought to determine why there was a divergence in 
dendrite complexity. Neurons with elevated levels of pUlk1 Ser757 correlated with 
increased complexity compared to low pUlk1 Ser757 (P<0.0001) (Fig. 2.6D,E). 
High pUlk1 Ser757 expression was defined as cells that had increased mean 
intensity by region of interest analysis compared to surrounding nonelectroporated 
cells in the same plane.  
Taken together, these results provide evidence that pUlk1 Ser757 
phosphorylation is required for neuron development, with ectopic Ulk1 expression 
causing defects unless inhibited. In this model, mTORC1 keeps Ulk1 levels in 









The goal of this study was to the ascertain the role of Ulk1 regulation in 
cortical neuron development using a gain-of-function approach, with a focus on 
potential dendritic morphological regulation. To begin, the Ulk1 regulator mTORC1 
was confirmed to be active in cortical neurons during development. Additionally, 
the percent colocalization of GFP with pS6 decreased as the neurons mature. 
Since plasmids dilute over time, GFP labeled neurons share similar birthdates. 
Figure 2.6 Ectopic Ulk1 expression leads to defective neuron development. 
A,B. Morphology of P14 GFP control or Ulk1 electroporated neurons in the SSC 
following IUE. C. Percent frequency histogram for the number of crossings of 
each P14 Control GFP and Ulk1 neurons (Control N=3, n=39; Ulk1 N=4, n=37). 
D. IHC of pUlk1 Ser757 in Ulk1 electroporated neurons following IUE. E. 
Number of crossings analysis on P14 Ulk1 neurons with high versus low pUlk1 
757 expression (High N=3, n=19; Low N=3, n=21). F. P14 number of crossings 
analysis for all control versus Ulk1 electroporated neurons (Control N=3, n=39; 





This means that levels of mTORC1 activity decrease as neurons complete the 
maturation process. At P14, ~40% of GFP positive neurons were pS6 positive 
compared to under 10% percent at P30. In the same time frame, cortical neurons 
underwent basal dendrite outgrowth. The levels of growth were consistent based 
on timepoints analyzed in our prior studies (20). Based on the findings of both 
papers, it demonstrates that dendrites are growing more rapidly from P0 to P21, 
with a change in peak complexity within 100 microns over 4 crossings, compared 
to ~2.5 crossings from P14 to P30.  
To confirm if the established relationship between mTOR and Ulk1 is 
conserved in the brain, in vitro pharmacological experiments using the mTOR 
inhibitors Torin1 and rapamycin were performed on primary mouse neurons. 
Torin1, and to a lesser extent rapamycin, reduced pUlk1 Ser757 levels. This 
indicated that just like reported in other systems, mTOR is indeed regulating Ulk1 
in neural cells. Additionally, Ulk1 and pUlk1 Ser757 is readily detected both by 
western blot of cortical lysates, as well as by IHC of the cerebral cortex in vivo. 
Interestingly, since pUlk1 Ser757 was also detected, it was tempting to speculate 
that this inhibition is required for neuron development, with mTORC1 keeping Ulk1 
activity in check.   
In utero electroporations were performed using a CAG Ulk1 plasmid co-
electroporated with GFP at e15.5. A co-requisite for in utero electroporation is the 
use of a CAG promoter to drive target protein expression because many promoters 
are inactive in neurons by P14 (74). CAG promoter driven Ulk1 resulted in 
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defective dendrite outgrowth. This is not surprising due to the necessity of Ulk1 
evident from previous knockout studies (66). Interestingly, during examination we 
observed Ulk1 overexpressed neurons that exhibited relatively normal dendrite 
complexity compared to controls. Due to the presence of endogenous pUlk1 
Ser757 phosphorylation, we wondered to what extent mTOR activity could be 
inhibiting the overexpressed Ulk1. To test this, we performed IHC for pUlk1 Ser757 
and found that a subset of Ulk1 overexpressed neurons exhibited heightened 
pUlk1 Ser757 levels. Moreover, the neurons with increased pUlk1 Ser757 
expression on average had a morphology comparable to controls. This would 
indicate that not only does ectopic Ulk1 have detrimental effects on neuron 
development, but also that mTORC1 inhibition of Ulk1 by Ser757 phosphorylation 
is required. Taken together, these findings provide evidence that Ulk1 inhibition is 
required for proper neuron development, and ectopic Ulk1 results in defective 
morphology if not inhibited. In this model, neuron Ulk1 activity is thus kept in check, 























A version of this data is published in Human Molecular Genetics: 
 
 
Sokolov, A. M., Holmberg, J. C. and Feliciano, D. M. (2020) The amino acid 
transporter Slc7a5 regulates the mTOR pathway and is required for granule cell 




























Pathogenic mutations in the SLC7A5 gene, which encodes an amino acid 
transporter, causes microcephaly and seizures. However, the mechanisms 
responsible for these phenotypes are unclear. Models have demonstrated that 
mouse Slc7a5 deletion is embryonic lethal and that these embryos lack a fully 
formed telencephalon. This phenotype is similar to mTOR deletion or inhibition. 
Notably, in many cells Slc7a5 import of amino acids is required to maintain mTOR 
activity. Slc7a5 is present within neurogenic regions during embryogenesis, is 
found in cultured neurons, and can modulate neuronal electrophysiological 
properties. However, Slc7a5 is also highly expressed within endothelial cells of the 
blood-brain barrier where removal in conditional mice leads to severe behavioral 
defects and non-cell autonomous changes in neurons. Therefore, the extent that 
neural Slc7a5 is required for development is unclear.   
Here, subventricular zone neural stem cells that generate olfactory bulb 
granule cells were electroporated with SLC7A5 or Slc7a5 short hairpin RNA 
encoding plasmids. Although early phases of neural development were unaltered, 
Slc7a5 knockdown effected late phases of granule cell dendrite maturation and 
survival. Slc7a5 knockdown also decreased mTOR pathway activity. Ras homolog 
enriched in brain, an mTOR activator, rescued the effect of Slc7a5 knockdown on 
mTOR pathway activity and dendrite arbors. The data presented here demonstrate 
that Slc7a5 is required for granule cell mTOR pathway activity, maturation, and 
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survival, which may help explain why Slc7a5 mutations prevent normal brain 











































Inactivating mutations in the SLC7A5 gene lead to a neurodevelopmental 
disorder characterized by microcephaly, seizures, and neuropsychiatric 
manifestations (53). SLC7A5 single nucleotide polymorphisms, copy number 
variants, and altered expression are also associated with a wide range of 
neuropathologies (55,75–79). Slc7a5 deletion is embryonic lethal and leads to 
robust neural defects in mice (52,54). Slc7a5 is expressed within embryonic 
cultures of cortical neurons, the developing neural tube and forebrain, and in 
postnatal neurogenic regions (54,80,81). Slc7a5 also regulates Kv1.2 dendritic 
voltage gated potassium channels in developing hippocampal neurons (56). Thus, 
at first appearance, Slc7a5 seems to play an important role in nervous system 
development. However, expression is notably absent from mature neurons in the 
adult nervous system where it appears confined to endothelial cells of the blood 
brain barrier (BBB) (53,82). Slc7a5 deletion from the developing BBB causes 
behavioral defects and changes in neuronal excitatory/inhibitory balance in mice 
(53). Notably, mice with Slc7a5 deletion from the BBB had no reported brain 
architectural defects whereas patients with Slc7a5 mutations and Slc7a5 knockout 
mouse brains are severely altered (53,54). Therefore, whether Slc7a5 has a cell 
autonomous role in neural cells requires further clarification.  
Slc7a5 is an evolutionarily conserved transporter that facilitates cellular 
uptake of neutral amino acids (83–85). Slc7a5 is associated with Slc3a2 in a 
heteromeric complex and together function as an amino acid antiporter (50). 
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Notably, Slc7a5 transports leucine into cells (50,83). Leucine is an anabolic amino 
acid that stimulates the protein kinase mTOR, resulting in protein translation and 
cell growth (86–94). Leucine binds to and prevents an interaction between Sestrins 
and a protein complex called GATOR2 (89). This allows GATOR2 to inhibit a 
GTPase activating protein, GATOR1 (89,91). GATOR1 inhibits lysosomal RAG 
heterodimeric GTPases that are responsible for mTOR docking at the surface of 
the lysosome (90). mTOR docking at the lysosome is required for mTOR activity 
because the GTPase Rheb is also localized to the lysosome with TSC1/2, which 
are Rheb GTPase activating proteins (37,38). Amino acids cause TSC1/2 
lysosomal dissociation, mTOR docking at the lysosome with RAGs, and mTOR 















Figure 3.1 Leucine induces mTORC1 activity through the Sestrin2-
Rag GTPases signaling cascade. A. The Sestrin2-Rag GTPase 
signaling cascade without leucine. B. The Sestrin2-Rag GTPase 
signaling cascade with leucine, resulting in mTORC1 recruitment to 
the lysosomal surface to be activated. 
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Here I performed electroporations neonatally as opposed to in utero, where 
the plasmid is injected into the lateral ventricle at P0. Subventricular zone (SVZ) 
NSCs located along the lateral ventricles comprise the largest postnatal 
neurogenic compartment in the brain (95). SVZ NSCs generate neuroblasts that 
migrate through the rostral migratory stream (RMS) into the olfactory bulb (OB) 
where approximately 94% mature into inhibitory granule cells (GCs) (95–99). GCs 
typically form dendrodendritic reciprocal synapses via their apical dendrite with 
mitral and tufted cells of the olfactory bulb. The role of Slc7a5 in SVZ neurogenesis 
and GC maturation was examined. RNA interference (RNAi) resulting in Slc7a5 
knockdown in vivo dramatically altered late phases of GC dendrite maturation and 
GC survival. Furthermore, Slc7a5 knockdown reduced mTOR pathway activity. 
Importantly, mTORC1 activation rescued Slc7a5 knockdown effects on GC 
maturation. The results of this study provide evidence that Slc7a5 regulates GC 





CAG-Rheb (a kind gift from Dr. Seonhee Kim) and CAG-tdTomato 
(Addgene #83029, a kind give from Dr. Angelique Bordey) have been described 
elsewhere (65,66). CAG-SLC7A5 was synthesized by a commercial vendor 
(SignaGen Laboratories). shSlc7a5 (Sigma Aldrich, TRCN0000443348 and 
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supplemental TRCN0000426198), control (Sigma Aldrich empty vector), CAG-
GFP (Addgene #11150) and CMV-myc-Slc7a5 (Slc7a5 NM_011404 Mouse 
Tagged ORF Clone, Origene) plasmids are available through the indicated 
commercial vendors. 
 
Neuro-2a cell culture and transfection 
  Neuro-2a mouse neuroblastoma cells (American Type Culture Collection 
CCL-131) were maintained in Dulbecco’s modified Eagle’s medium (DMEM), 10% 
fetal bovine serum, and penicillin/streptomycin in tissue culture-treated polystyrene 
flasks (Falcon; BD Biosciences Discovery Labware) in a 37°C incubator with 5% 
CO2. Neuro-2a cells were passaged at a density of 4 x 105 cells into 6 well plates 
24 hours prior to transfection. PolyJet (SignaGen Laboratories) was mixed at a 3:1 
ratio with plasmid DNA in DMEM and approximately 1 µg of plasmid was added to 
each well. 
 
Neonatal electroporation  
Timed pregnant CD-1 mice were delivered from Charles River Laboratories, 
acclimated to the animal facility, and the date of birth was recorded. Neonatal mice 
(P0-P1) were injected with equal amounts, concentrations, and volumes of DNA 
plasmids (~1.3-2.0 µg/µL) diluted in PBS with 0.1% fast green. DNA was injected 
into the lateral ventricles illuminated with a fiber optic light source and delivered 
using a UV sterilized borosilicate glass micropipette generated from capillary tubes 
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as previously described (67). Borosilicate capillary tubes were pulled with a P97 
Sutter micropipette puller with the settings. Tweezer electrodes (model 520; BTX) 
were rinsed in 0.9% saline solution and placed on the heads of the pups, and five, 
100-volt square pulses of 50 ms duration with 950-ms intervals were applied using 
a pulse generator (ECM830; BTX). 
 
Image analysis 
20× images were uploaded and analyzed using Fiji (ImageJ 1.5g). Simple 
Neurite Tracer plug-in was used to trace dendrite processes of 23-58 RFP positive 
cells from 3-6 mice per condition. Sholl analysis was performed at 10 µm intervals 
to quantify both apical and basal dendritic arborization using the Sholl plug-in. Total 
number of dendritic crossings were calculated by taking the sum of crossings at 1 
μm intervals for each traced neuron and averaging the total number of crossings 
per neuron in each condition. The number of labeled OB GCs from 3-8 mice was 
quantified using Fiji cell counter plugin. 20× images of RFP positive OB GCs 
stained by immunohistochemistry were uploaded to Fiji (ImageJ 1.5g). The 
freehand selection tool was used to trace a region of interest on electroporated 
cells and record a mean gray value to quantify the staining intensity of pS6 in 
indicated conditions. Pairwise comparison of staining in non-electroporated cells 
in the same Z section was performed. Staining was performed on 3-5 mice per 
condition and 33-60 cells per condition. 
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Slice preparation and immunohistochemistry  
Performed as described in Chapter I. Primary antibodies used were pS6 
(rabbit anti-pS6; 1:1000; Cell Signaling Technology; Ser 240/244, 61H9, #4838), 
or SLC7A5 (rabbit anti-SLC7A5; 1:1000; Cell Signaling Technology; #5347) 
overnight at 4°C. After three washes in PBS containing 0.1% Tween-20, slices 
were incubated with the appropriate secondary antibody (Alexa Fluor series at 
1:500 [Invitrogen]) overnight at 4°C. TO-PRO-3 (Invitrogen) was used to counter-
stain sections. Each staining was replicated on 4-6 mice per condition.  
 
Western blotting  
Performed as described in Chapter II with the following antibodies: rabbit 
anti-SLC7A5 (1:1,000; Cell Signaling Technology; #5347), rabbit anti-myc-tag 
(1:1,000; Cell Signaling Technology; 71D10, #2278), and rabbit anti-Akt (pan) 
(1:1,000; Cell Signaling Technology; 11E7, #4685). Blots were visualized using 
Bio-Rad Chemidoc MP imaging system. PVDF membranes were stripped for 5-15 
min at room temperature using Restore Western Blot Stripping Buffer (#21059, 
Thermo Fisher Scientific) prior to probing for loading controls. 
 
Leucine Assay 
 4 x 105 Neuro-2A cells were seeded into 6 well plates and transfected 24 
hours later with DNA plasmids. After 48 hours, cells were lysed, and leucine levels 
were measured by performing a leucine assay following manufacturer instructions 
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(Sigma-Aldrich, MAK003). 10 µL of lysate was added to a 96 well plate and diluted 
to 50 µL using assay buffer. Next, 46 µL of assay buffer was added to each well, 
along with 2 µL of BCAA enzyme mix and substrate mix for a final volume of 100 
µL per well. Blanks were performed by mixing lysate with assay buffer and 
substrate mix but omitting enzyme. The blank absorbances were subtracted from 
lysate absorbances. A standard curve was generated with pure leucine. Readings 




bDNA FISH was performed using the Quantigene ViewRNA ISH Cell assay 
according to the manufacturer’s instructions. Briefly, 4% paraformaldehyde fixed 
tissue that was washed three times in PBS and permeabilized with Detergent 
Solution QC followed by two rinses with PBS. Tissue was incubated in Protease 
QS solution at 40°C for 60 minutes. Tissue sections was then incubated with Probe 
Set Diluent QF with or without Slc7a5 probe set type 4 (Alexa Fluor 488) for 3 hr 
at 40°C. Tissue was washed in 2 mL wash buffer for 5 min two times and then 
incubated for 30 min at 40°C with PreAmplifier Mix and Amplifier Diluent QF pre-
warmed to 40°C. Samples were washed three times with 2 mL wash buffer for 5 
min each wash. Next, tissue was incubated with 400 mL of the Label Probe Mix 
diluted in Label Probe Diluent QF (pre-warmed to 40°C) for 30 min at 40°C. 
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Samples were then washed three times in 2 mL wash buffer for 10 min, 
counterstained, and mounted in ProLong Gold Antifade mounting reagent. 
 
RT-PCR  
OBs from mice were removed from ~P30 mice and subjected to TRIzol RNA 
isolation according to the manufacturer’s protocol. Briefly, An OB was added to 
~250 µL of TRIzol reagent and passed through a 22-gauge needle into 1.5 mL 
reaction tubes. Samples were incubated at 4°C for 10 min. 50 µL of chloroform 
was added to each tube, vortexed, and incubated for 10 min at 4°C. Samples were 
centrifuged for 10 min at 12,000 x g at 4°C and the upper aqueous phase was 
transferred to a fresh tube. 125 µL ice cold isopropanol was added to the aqueous 
phase, samples incubated at 4°C for 10 min, and then centrifuged for 10 min at 
12,000 x g at 4°C. Supernatant was discarded and RNA pellets washed in 250 µL 
of 75% ethanol, vortexed, and centrifuged for 5 min at 7,500 x g. Samples were 
washed a total of three times and the RNA pellet was air dried for 10 min and 
resuspended in 50 µL of RNAase-free water prior to determining concentration and 
purity. For reverse transcription polymerase chain reaction (RTPCR), RNA was 
combined with deoxynucleotide triphosphates (dNTPs), random primers 
(Invitrogen), and Rnase/Dnase-free H2O. Samples were heated for 5 min at 65°C 
and then rapidly chilled. Dithiothreitol, Rnase out, and SuperScript III were then 
added to each sample and reverse transcribed. cDNA was subjected to PCR using 
primers to Slc7a5 and Platinum Taq polymerase. 
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Statistics  
Data were graphed and analyzed with GraphPad Prism software (Version 
8.2.0, GraphPad Software Inc.). Statistical significance was determined by 
Student’s T-test (cell number analysis), one-way ANOVA (Western blots, ROI and 
total number of crossings analysis) with multiple comparisons test, or two-way 
ANOVA with Tukey’s multiple comparisons test (Sholl analysis). All experiments 
were performed on 3- 8 mice per condition per timepoint.  
 
Results 
In vitro and in vivo genetic Slc7a5 manipulation. 
  Neuro-2a cells are a cancerous cell-line of neural origin that have high 
transfection efficiency and are routinely used to study the mTOR pathway 
(100,101). Neuro-2a cells were transfected with the human form of SLC7A5 under 
the control of a CAG promoter. This plasmid increased SLC7A5 expression by 
~100-fold as determined by western blot using an antibody that detects only the 
human form of SLC7A5 (P<0.001) (Fig. 3.2.I A). Neuro-2a cells were also 
transfected with a plasmid encoding mouse Slc7a5 fused to a myc-tag epitope 
because no commercially available antibodies to Slc7a5 faithfully recognized 
mouse Slc7a5 (data not shown). Slc7a5 was increased (P<0.0001) as determined 
by western blot using an antibody to myc (Fig. 3.2.I B). In addition, a plasmid 
encoding short hairpin (sh) RNA to Slc7a5 (shSlc7a5) was co-transfected with 
mouse Slc7a5. Short hairpin RNA (shRNA) mediated knockdown of Slc7a5 was 
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validated by western blot with the antibody to myc and reduced Slc7a5 by ~71% 
(P<0.0001) (Fig 3.2.I B). These results mirrored the effect of shSlc7a5 on myc-
Slc7a5 when compared with cells transfected with a control shRNA 
and Slc7a5 (Fig. 3.2.II A). Moreover, shSlc7a5 reduced leucine import (Fig. 3.2.II 
B). 
  P0 mouse SVZ NSCs were electroporated with red fluorescent protein 
(RFP) and empty vector control, shSlc7a5, or SLC7A5 encoding plasmids. SVZ 
NSCs give rise to neuroblasts that migrate along the RMS, enter into the OB 
~7 days later, take an additional 7 days to extend dendrites into the GC layer, and 
take ~16 more days to fully mature (Fig. 3.2.I C) (102). Brains were therefore 
harvested and examined at P14 and P30. IHC with an antibody to human SLC7A5 
revealed robust expression in RFP and SLC7A5 co-electroporated cells in the SVZ 
(Fig. 3.2.I D,E). The number of SLC7A5 or shSlc7a5 cells in the SVZ did not 
change in comparison to controls at P14 or P30 (Fig. 3.2.I F-L). Slc7a5 knockdown 
was confirmed to persist in vivo at P30 (Fig. 3.2.III A). Slc7a5 protein is expressed 
within the SVZ, RMS and OB (81). In situ hybridization (ISH) from the Allen 
Institute confirmed Slc7a5 expression in OBs (Fig. 3.2.III B). Slc7a5 expression 
was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) (Fig. 
3.2.III C). bDNA fluorescence in situ hybridization (FISH) demonstrated that 
Slc7a5 mRNA was present in the GC layer (Fig. 3.2.III D,G). bDNA FISH was then 
performed in RFP electroporated brains which confirmed expression within GCs 
(Fig. 3.2.III E,F,H). OBs of the electroporated mice were next examined because 
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neurons do not develop properly in Slc7a5 knockout mice and because patients 









Figure 3.2.I In vitro and in vivo genetic Slc7a5 manipulation. A. Western blot 
for SLC7A5 following control or SLC7A5 plasmid transfection of Neuro-2a cells 
(N=6, 6). B. Western blot for myc from lysates of Neuro-2a cells transfected 
with control, myc-Slc7a5 and control, or myc-Slc7a5 and Slc7a5 shRNA 
plasmids (N=3, 3, 3). C. Schematic diagram representing a sagittal section of 
the mouse brain. The diagram depicts electroporated (red) NSCs surrounding 
the LVs that generate neuroblasts that migrate through the RMS and enter the 
OB 7 days post-electroporation and become mature GCs 30 days post-
electroporation. D,E. 20x image of RFP+ cells co-electroporated with SLC7A5 
in the SVZ and stained for SLC7A5. Scalebar=50 μm. F-K. 5x images of P14 
and P30 SVZs following P0 co-electroporation with RFP and control, 
shSlc7a5, or SLC7A5 plasmids (P14 Control, N=6; shSlc7a5, N=6; or 
SLC7A5, N=3) (P30 control, N=7; shSlc7a5, N=8; or SLC7A5, N=4). 
Scalebar=100 μm. L. Quantification of F-K. LV=lateral ventricle, RMS=rostral 




















Figure 3.2.II Confirmation of Slc7a5 shRNA specificity and leucine transport. 
A. Western blot for myc from lysates of Neuro-2a cells transfected with control 
shRNA, shSlc7a5, control shRNA with myc-Slc7a5, or shSlc7a5 and myc-
Slc7a5 plasmids (N=3, 3, 3, 3). Westerns were stripped and re-probed for total 
Akt as a loading control. B. Leucine concentrations were measured in lysates 
from A. and demonstrate a reduction in leucine concentration following Slc7a5 
knockdown. (N=3, 3, 3, 3) *=P<0.05, ***=P<0.001.  ****=P<0.0001. 
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Figure 3.2.III Slc7a5 knockdown and OB GC expression. A. Quantification 
of Slc7a5 staining at P30 in control (SLC7A5, empty vector, and RFP) (n=92) 
or shSlc7a5 (SLC7A5, shSlc7a5, and RFP) electroporated cells (N=3, n=93). 
B. In situ hybridization of Slc7a5 in a P56 sagittal brain section from the Allen 
Mouse Brain Atlas. Image credit: Allen Institute. C. RT-PCR of mRNA from 
P30 OB. D. bDNA FISH for Slc7a5 mRNA (green spots) OB. (N=3) E. 
Overlap of RFP positive OB GCs (red) from P0 electroporations subjected to 
bDNA FISH (F) for Slc7a5 mRNA (green) (N=3). Arrows point to Slc7a5 
mRNA puncta staining in electroporated GC. G. Control label probe only for 
bDNA FISH in a section from the same brain shown in D. H. Overlap of RFP 
positive OB GCs (red) from P0 electroporations subjected to bDNA FISH (I) 
for control label probe only in a section from the same brain as E-F. Arrows 
indicate overlap of Slc7a5 in a GC. ****=P<0.0001. 
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Slc7a5 is required for late phases of dendrite maturation. 
 
  Fourteen days after neuroblasts migrate away from the SVZ, they have 
become immature neurons and have formed immature basal and apical dendrites 
that extend into the GC layer of the OB (102,103). Dendrite arborization was 
quantified in control, shSlc7a5 and SLC7A5 electroporated mice. P14 control GCs 
exhibited a morphology similar to what has previously been shown in rats and more 
recently in vivo in mice, having ~2.3 crossings within 50 μM of the cell soma, 
characteristic of basal dendrites and a singular immature apical projecting dendrite 
within the GC layer (Fig. 3.3.I A) (102,104). GC dendrite complexity was quantified 
by tracing electroporated GCs, performing Sholl analysis, and calculating the total 
number of dendrite crossings per GC. No significant changes to dendrite 
complexity or total number of crossings were detected in shSlc7a5 or SLC7A5 GCs 
compared with controls at P14 (Fig. 3.3.I A-E). 
  Additional phases of GC apical and basal dendrite growth and 
maturation occur until GCs are 30 days old (102,103,105). In agreement, P30 GC 
dendrite arbors appeared more complex than at P14 (Fig. 3.3.I A,F). There were 
more proximal (basal) and distal (apical) dendrite crossings (Fig. 3.3.I D,I). 
Moreover, the total number of dendrite crossings per GC increased from P14 to 
P30 (P<0.001) (Fig. 3.3.I E,J). In contrast, Slc7a5 knockdown dendrite arbors 
were critically reduced at P30 (Fig. 3.3.I G,I). Slc7a5 knockdown GCs had on 
average ~25% fewer crossings within 50 μM and apical processes were truncated 
(Fig. 3.3.I I). Moreover, Slc7a5 knockdown decreased the total number of dendrite 
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crossings per neuron at P30 (P<0.0001) (Fig. 3.3.I J). During the same period, 
SLC7A5 did not significantly change dendrite arborization further demonstrating 
the specificity of this effect (Fig. 3.3.I H-J). Reduced dendrite complexity and total 
number of crossings were verified with a second Slc7a5 shRNA (Fig. 3.3.II A,B). 
Additionally, at P30 frequency histogram profiles highlighted that many RFP 
positive cells in shSlc7a5 conditions had few to no dendrite processes and on 
average, GCs had a smaller soma size (Fig. 3.3.II C,D). Taken together, these 
results demonstrate that Slc7a5 is required for GCs to acquire and maintain mature 














Figure 3.3.I Slc7a5 is required for late phases of dendrite maturation. A-
C. 20× images of P14 OB GCs from P0 electroporation of RFP and control, 
shSlc7a5, or SLC7A5 plasmids. D. Sholl analysis of A-C (P14 Control N=6, 
n=44; shSlc7a5 N=4, n=58; SLC7A5 N=3, n=23). E. Total number of 
crossings per GC for A-C. F-H. 20× images of P30 GCs from P0 
electroporation of RFP and control, shSlc7a5, or SLC7A5 plasmids. I. 
Sholl analysis of F-H (P30 Control N=4, n=38; shSlc7a5 N=3, n=46; 
SLC7A5 N=4, n=37). J. Total number of crossings per GC for F-H. 







Figure 3.3.II Slc7a5 knockdown GC dendrites, frequency histogram profile, and cell 
size. A. Sholl analysis of P30 neurons following electroporation at P0 with RFP and a 
second shRNA (shSlc7a5 2) to Slc7a5 or control plasmids (N=3, 3). B. Total number 
of crossings per GC for A. (shSlc7a5 2, N=3, n=33 vs control, N=3, n=22). C. Frequency 
histogram profile of total dendrite crossings per GC at P30 following electroporation at 
P0 of control (N=4, n=38) or shSlc7a5 (N=3, n=46) plasmids. D. Cell size analysis of 
GCs at P30 following electroporation at P0 of control (N=4, n=1326) or shSlc7a5 
plasmids (N=3, n=450). ****=P<0.0001. 
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Slc7a5 is required for developing GC survival. 
 
  Initially, GC proximal dendrites found in the GC layer receive GABAergic 
input from surrounding GCs around P14 (103,105). By P30, dendrites reach the 
external plexiform layer to receive glutamatergic input from tufted and mitral cells 
that is critical for activity-dependent survival (102,103,105). Therefore, the extent 
that Slc7a5 GCs survive with an immature (P14) or without a mature (P30) dendrite 
arbor was determined. There was no difference in the number of RFP positive GCs 
between control or shSlc7a5 conditions at P14 (Fig. 3.4.I A-C). This is not 
surprising due to the absence of morphological defects by P14 following Slc7a5 
knockdown. However, by P30 a robust phenotype manifested, with 70% fewer 
GCs present after Slc7a5 knockdown compared with control (P<0.0001) (Fig. 3.4.I 
D-F). By P70, the phenotype worsened, with almost no RFP labeled Slc7a5 
knockdown GCs present in the OB (P<0.0001) (Fig. 3.4.I G-I). These findings were 
also confirmed at P30 using a GFP plasmid to rule out the effect being caused by 
RFP (P<0.01), as well as a second shRNA that targets Slc7a5 (P<0.001) (Fig. 
3.4.II A-J). The results from these experiments demonstrate that Slc7a5 is required 




Figure 3.4.I Slc7a5 is required for developing GC survival. A,B. 5× images of 
P14 OBs from P0 electroporation of RFP and control or shSlc7a5 plasmids. C. 
Relative number of RFP+ GCs at P14 for control or shSlc7a5 conditions. P14 
control, N=6; shSlc7a5, N=6. D,E. 5x images of P30 OBs from P0 
electroporation of RFP and control or shSlc7a5 plasmids. F. Relative number 
of RFP+ GCs at P30 for control or shSlc7a5 conditions. P30 control, N=7; 
shSlc7a5, N=8. G,H. 5x images of P70 OBs from P0 electroporation of RFP 
and control or shSlc7a5 plasmids. I. Relative number of RFP+ GCs at P70 for 
control or shSlc7a5 conditions (P70 control N=4; shSlc7a5 N=3). 
Scalebar=100 µm. ****=P<0.0001. 
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Figure 3.4.II Validation of GC death with an additional Slc7a5 shRNA. 
A-D. 5x P30 Obs or SVZs from mice electroporated with GFP and control 
or shSlc7a5 plasmids (Control, N=4; shSlc7a5, N=3). E. Quantification 
of A-D. F-I. 5x P30 OBs or SVZs from mice electroporated with RFP and 
control or a second alternative shRNA to Slc7a5 (Control N=3; shSlc7a5 
N=3). J. Quantification of F-I. SVZ=Subventricular zone. **=P<0.01, 
***=P<0.001. Scalebar=100 µm. 
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Slc7a5 regulation of dendrite maturation depends on mTOR. 
 
  Since Slc7a5 can regulate the mTOR pathway and the mTOR pathway 
regulates dendrite growth, it was tempting to speculate that the defects seen 
following Slc7a5 knockdown could be caused by decreased mTOR pathway 
activity (50,54,91,93,106). Ectopic Rheb binds to and activates mTORC1 in the 
absence of leucine (107,108). It was hypothesized that if this occurred, over-
expression of Rheb, a direct activator of mTORC1, might be able to overcome the 
effect of Slc7a5 knockdown. To begin to address this hypothesis, littermates were 
co-electroporated with RFP and control, Rheb, shSlc7a5, or shSlc7a5 and Rheb 
plasmids. IHC was subsequently performed for pS6 at P30. As expected, Slc7a5 
knockdown decreased pS6 by ~29% (P<0.0001) (Fig. 3.5.I A,B). This result 
confirms that Slc7a5 regulates the mTOR pathway. Also as predicted, Rheb 
littermates had ~26% more pS6 compared with control (P<0.0001) (Fig. 3.5.I A,B). 
Notably, and as hypothesized, Slc7a5 knockdown GCs co-electroporated with 
Rheb had pS6 levels completely rescued compared with control (Fig. 3.5.I A,B). 
 Since mTOR pathway activity was rescued in Slc7a5 knockdown GCs co-
electroporated with Rheb, we wondered to what extent Rheb might also mitigate 
dendrite defects in Slc7a5 knockdown GCs. First, dendrite morphology was 
measured in control or Rheb electroporated GCs. Rheb by itself increased dendrite 
complexity in agreement with increased pS6, similar to previous reports (P<0.001) 
(Fig. 3.5.I C,E,G,H) (20,30). Consistent with Figure 3.3.I, Slc7a5 knockdown 
decreased GC dendrite complexity compared with control (Fig. 3.5.I C,D,G,H). In 
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contrast, shSlc7a5 and Rheb co-electroporated dendrite complexity was partially 
rescued compared with Slc7a5 knockdown GCs (Fig. 3.5.I C,F,G). In addition to 
Sholl analysis, the total number of crossings per GC was calculated. As expected, 
shSlc7a5 GCs had ~53% fewer total crossings compared with controls, and this 
decrease was rescued by Rheb (P<0.0001) (Fig. 3.5.I H). In shSlc7a5 OBs, there 
was a 74% reduction in GCs compared with control OBs (P<0.0001) (Fig. 3.5.II). 
However, Rheb co-electroporation increased the number of GCs to 220% of 
shSlc7a5 alone (P<0.05) (Fig. 3.5.II). These results demonstrate that Slc7a5 is 























Figure 3.5.I Slc7a5 regulation of dendrite maturation depends on mTOR. 
A. Images of P30 GCs from RFP and control, shSlc7a5, Rheb, or shSlc7a5 
with Rheb plasmids, stained for pS6. Scalebar=12.5 µm. B. Quantification 
of pS6 staining intensity for A (Control N=3, n=39; shSlc7a5 N=5, n=33; 
Rheb N=3, n=37; shSlc7a5 and Rheb N=5, n=60 C-F. 20x images of P30 
GCs from P0 electroporation of RFP and control, shSlc7a5, Rheb, or 
shSlc7a5 and Rheb plasmids. Scalebar=50 µm. G. Sholl analysis for C-F. 
H. Total number of crossings per GC for C-F (Control N=3, n=23; shSlc7a5 











Mutations in Slc7a5 and components of the mTOR pathway result in 
abnormal brain development and neurological manifestations. The evidence 
presented here supports the hypothesis that Slc7a5 regulates mTOR pathway 
activity and is required for neonatal OB GC dendrite maturation and survival. SVZ 
NSCs were electroporated neonatally with Slc7a5 shRNA or SLC7A5 to attempt 
to address the relative contribution of Slc7a5 to neural development. SVZ NSCs 
generate neuroblasts that migrate through the RMS into the OB. The majority of 
the neurons matures into inhibitory GCs of the GC layer and continues to mature 
over a 30 day period (102,103,105). Slc7a5 knockdown did not change the number 
Figure 3.5.II ShSlc7a5 neuron survival following mTORC1 
hyperactivation. Relative number of RFP+ GCs at P30 for control 
(N=7), shSlc7a5 (N=8), Rheb (N=4), and shSlc7a5 and Rheb (N=5). 
*=P<0.05. **=P<0.01. *****=P<0.0001. 
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of cells in the SVZ at P14 or P30. SVZ NSCs rapidly dilute electroporated plasmids 
into daughter cells, and therefore it could be argued that knockdown did not occur 
in the time required to see an effect. However, knockdown in vitro occurred within 
2 days, indicating that this is not a likely possibility. Although Slc7a5 knockdown 
occurs rapidly, it could take a longer period of Slc7a5 depletion to exert an effect. 
The fact that equal numbers of NSCs retain plasmid DNA and hence were 
fluorescent at P14 and P30 would argue against time-dependent depletion being 
critical for the survival of NSCs but could affect rates of proliferation or 
differentiation. 
Surprisingly, the quantity and morphology of Slc7a5 knockdown GCs did 
not significantly differ from controls at P14. At this time of development, GC 
dendrite arbors are immature and are able to respond electrophysiologically to 
GABA but not glutamate (103,105). Robust dendrite arborization, spine formation 
and electrophysiological responses of GCs to glutamate occur later, at ~28–
30 days, when dendrodendritic synapses are maturing in the external plexiform 
layer (102,103,105). The results presented here support the notion of continued 
GC dendrite growth into the external plexiform layer from P14 to P30. 
We found that dendrites were critically malformed at P30. Mechanistically, 
this was associated with reduced mTOR pathway activity. Slc7a5 knockdown 
reduced leucine levels in Neuro-2a cells. Leucine binds to Sestrin2 to modulate 
mTORC1 (88). The ratio of phospho-4E-BP to total 4E-BP, a measure of mTOR, 
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is reduced in BBB Slc7a5 knockout mice (53). In comparison, Slc7a5 null embryos 
had reduced pS6 potentially indicative of aberrant mTOR (54). Therefore, an 
alternative interpretation of the current study is that there may be a loss in the 
regulation of mTOR as opposed to strict loss of mTOR activation. Abnormal 
dendrite arborization is a shared characteristic in a range of neurodevelopmental 
disorders and these patients often present with neurological manifestations 
including epilepsy that are indicative of hyper-connectivity. As an indication of an 
active role of mTOR in the pathogenesis of epilepsy, mTORC1 inhibitors such as 
the rapalogs decrease the frequency or severity of seizures in a disease with 
elevated mTORC1 activity (109). In further support of the role that mTORC1 has 
in dendrite morphology, ectopic Rheb expression increased dendrite arborization 
similar to previous reports (20,30). Moreover, co-electroporation of Rheb partially 
rescued the effect of Slc7a5 knockdown on survival. Ectopic Rheb binds to and 
activates mTORC1 in the absence of leucine (107,108). It is therefore not 
surprising that Rheb rescued the effect of Slc7a5 knockdown on dendrites. 
Engineered deletion of mTOR exons 1–5 causes embryonic day 6.5–7.5 
lethality (110). A mutagenic screen identified an intronic mutation leading to 
reduced mTOR-prevented development of the telencephalon and led to death by 
embryonic day 11 (111). The phenotype of mutant mTOR mirrors the phenotype 
of a group of Slc7a5 knockout mice (54). This is similar to conditional mTOR 
deletion using Nestin promoter-driven recombination (Cre), which causes 
microcephaly and a thinning of the cortical plate by embryonic day 15 (39). 
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Microcephaly in the mTOR conditional mice is correlated with reduced progenitor 
proliferation and neurogenesis. However, mTOR is present within two complexes, 
mTORC1 and mTORC2. Therefore, to what extent mTORC1, mTORC2, or both 
are responsible for mTOR deletion phenotypes is not clear. Surprisingly, Nestin-
Cre deletion of rictor or raptor, which are the components of mTORC2 and 
mTORC1 respectively, phenocopy Nestin-Cre deletion of mTOR (112,113). 
Conditional raptor deletion also reduces progenitor proliferation and dendrite 
growth of neurons, and induces robust apoptosis within cortical plate neurons 
(113). However, these mice also have robust changes in gliogenesis. Nestin-Cre 
rictor deletion similarly produces neurons with reduced dendrite arbors (112). 
Thus, both mTORC1 and mTORC2 appear to be required for proper dendrite 
morphology. Perhaps, more pertinent to this paper is the observation that 
mTORC1 activity is high within the SVZ-RMS-OB axis, including in OB GCs where 
translation becomes highly selective (44). mTORC1 knockdown in NSCs prevents 
neuronal differentiation and provides evidence of the importance of mTORC1 
regulation in neural differentiation (114). Indeed, rictor, raptor, and mTOR 
knockdown as well as mTOR or raptor deletion by neonatal electroporation of SVZ 
NSCs reduces OB GC mTORC1 activity and dendrite growth (115). These results 
are consistent with previous observations that removal of negative regulators of 
mTOR, such as TSC1/2, increase dendrite growth (42). Taken together, the loss 
of Slc7a5 resulting in reduced or abnormal mTOR activity is consistent with current 
models of how mTORC1 regulates OB GC maturation. 
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A limitation of this study is that although Slc7a5 transports leucine, 
numerous other amino acids, dopamine, and thyroid hormones (83–85,116,117). 
Although the current study demonstrates that Slc7a5 is required for leucine 
transport, it does not address whether other molecules are involved in the 
requirement for Slc7a5 or whether compensatory changes may contribute to our 
findings and further experimentation is required in future studies. A major question 
that arises from these studies is why certain cells do not require Slc7a5, although 
the existence of other transporters and mechanisms of acquiring nutrients such as 
autophagy or micropinocytosis are possible. In summary, the results of this study 
highlight the existence of a transient and cell-specific requirement for Slc7a5 to 











Granule cell defects in Tsc2NSC-/- mice 
Abstract 
Tuberous Sclerosis Complex (TSC) is a multisystem disorder that results in 
disrupted brain development, including aberrations in neuron morphology and the 
formation of cortical tubers that are linked to cognitive defects and seizures. 
Megalencephaly also frequently occurs from unchecked anabolic growth. TSC is 
caused by a single inactivating gene mutation in TSC1 or TSC2, which takes away 
the “brakes” on the pro-anabolic kinase mTORC1 and results in its upregulation. 
Current treatments for TSC solely focus on symptom alleviation, such as surgery 
to remove growths/tubers, anti-seizure drugs, and mTOR inhibitors. While helpful, 
these treatments do not address many underlying neurological manifestations 
associated with TSC patients. As seizure onset often occurs during the first year, 
and early onset seizures are linked to cognitive defects, earlier proactive treatment 
may alleviate cognitive symptoms of TSC. Uncovering underlying mechanisms in 
which TSC results in altered brain development could lead to new avenues of 
treatment, not only for TSC patients but also for other mTORopathies such as 
Autism Spectrum Disorder and epilepsy. Utilizing Cre-lox technology, we use two 
different models to investigate neurological defects following global and region-
specific Tsc2 deletion. First, we generated an inducible neural stem cell specific 
Tsc2 knockout mouse, which underwent widespread recombination following 
intraperitoneal injection with tamoxifen. To birthdate neurons and study region-
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specific effects of Tsc2 inactivation in the olfactory bulb, we also delivered DNA 
plasmids encoding GFP and Cre recombinase into NSCs of the lateral ventricles 
via neonatal electroporation into Tsc2fl/fl mice. Following Tsc2 inactivation, 
olfactory bulb granule cells were found to have increased soma size and more 
complex dendrite arborization. These findings demonstrate that our mouse model 
exhibits a consistent TSC phenotype similar to patients and serves as an excellent 


















Tuberous Sclerosis Complex (TSC) is a multisystem disorder that effects 
~1:8000 people, with as many as 50% of TSC patients having intellectual 
disabilities and ~40% being on the autism spectrum (118–120). The vast majority 
also suffer from seizures that are detrimental to brain development. Cognitive and 
behavioral issues as well as seizures manifest in TSC partly due to altered cortical 
neuron connectivity and the formation of cortical tubers. Cortical tubers consist of 
mislaminated dysmorphic/giant neurons in the cortex (120,121). TSC patients also 
commonly develop growths in the LV that can cause hydrocephalus due to 
pressure buildup (122,123). TSC was first described by Désiré-Magloire 
Bourneville in 1880 as Bourneville disease following an autopsy on a young female 
with intellectual disabilities that suffered from seizures (124). He discovered that 
she had lesions in multiple regions in her body as well as cortical tubers, which he 
attributed as the potential cause of the neurological issues. Our knowledge of TSC 
and how to treat it has grown substantially since this time, with most current 
therapeutic intervention involving mTOR inhibitors (i.e. rapamycin). While helpful, 
earlier more effective treatment options are essential to improve patient quality of 
life.  
TSC is a genetic disorder caused by an inactivating mutation in TSC1 or 
TSC2, which encodes for Hamartin (TSC1) and Tuberin (TSC2). These proteins 
form a GTPase activating protein complex that inhibits mTORC1 by activating 
Rheb GTPase activity (38,125,126). mTORC1 is a protein kinase which drives 
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mRNA translation and cellular growth while inhibiting certain catabolic functions 
(127). Typically patients have one mutant allele that is either inherited from one 
parent (one-third of patients) or occurs sporadically (two-thirds of patients) in either 
germline or somatic cells (128). This results in a loss of heterozygosity, and 
explains the somatic mosaicism found in patients, with a subset of cells exhibiting 
TSC1/2 inactivation (129,130). TSC1/2 inactivation results in upregulated 
mTORC1 activity, classifying TSC as a mTORopathy.  
Since TSC is caused by a single gene mutation, Tsc1/2 transgenic mice 
have been a valuable tool in TSC research as well as a model for neuron 
development. Tsc1/2 homozygous mutant mice are embryonic lethal; thus the use 
of conditional knockouts is required (131,132). There are various conditional Tsc1 
knockout mouse models that exhibit defective brain development and seizures. 
Many of these models utilize Cre-recombinase technology to induce targeted 
deletion of TSC. Previous studies have utilized transgenic Tsc1 mice expressing 
Cre under the control of neural stem cell/progenitor-specific promoters including 
GFAP, Nestin, and Emx1. These conditional Tsc1 knockout mice exhibited 
decreased survival, NSC differentiation and cell fate defects, as well as neuron 
cytomegaly, ectopic migration, and seizures (133–136). It is important to note that 
while GFAP was solely considered an astrocyte marker, it is now widely known to 
target NSCs as well. Tsc1 deletion in neurons have also been explored using 
CamK2a and Synapsin Cre promoters, and resulted in similar developmental 
defects such as altered neuron morphology, ectopic migration, decreased survival, 
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and seizures (137–139). Tsc2 studies have used GFAP-Cre Tsc2 mice and also 
documented similar developmental defects to Tsc1 knockout models (140,141). 
Taken together, these models demonstrate that Tsc1/2 removal in NSCs, 
neurons, or astrocytes result in various brain development defects that partially 
phenocopy defects seen in patients. While much has been learned about 
neurogenesis using these models, further research is needed. For one, many 
previous studies have used knockout models that target Tsc1 as opposed to Tsc2, 
despite Tsc2 mutations resulting in a more severe phenotype (128,142,143). The 
difference in severity is likely due to the distinct roles of TSC1/2. TSC2 encodes 
for the GAP domain, which regulates Rheb GTPase activation, whereas TSC1 
provides complex stabilization (126). Additionally, many models do not utilize a 
Cre activated fluorescent transgene, such as tdTOMATO, to confirm that any 
changes in specific cells are an autonomous effect. This is an important distinction 
as seizures frequently occur in the TSC phenotype and this can result in secondary 
effects on neurons. 
We propose to generate a NSC conditional Tsc2 knockout mouse colony 
by crossing Tsc2fl/fl and Nestin-CreERT2 tdTOMATOMut/Mut mice into homozygosity. 
The Tsc2fl/fl mice contain LoxP sites flanking exons 2-4 of the Tsc2 gene (144) . 
Excision of Tsc2 at these sites prevents Tsc2 (tuberin) from forming a complex 
with Tsc1 (hamartin) and results in Tsc2 (tuberin) degradation via ubiquitination 
(145,146). Nestin-CreERT2 tdTOMATOMut/Mut mice express a fusion protein of Cre 
recombinase with the modified estrogen receptor (ERT2) that is activated by 
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tamoxifen (TX) and results in Tsc2 deletion. Expression of CreERT2 is driven by 
the Nestin promoter, which results in specific Tsc2 deletion in neural 
stem/progenitor cells. The tdTOMATO resides after a LoxP floxed STOP 
sequence. Thus, tdTOMATO allows for the visualization of cells that have 
underwent recombination, validating both CreERT2 activation while providing a 
built-in control to confirm specificity of Nestin-CreERT2 activation. As highlighted 
previously, tdTOMATO fluorescence also provides confirmation that analyzed cells 
have underwent recombination. The resulting progeny will be Tsc2fl/fl; Nestin-
CreERT2; tdTOMATOMut/Mut mice (referred herein as Tsc2NSC-/- mice). To induce 
widespread TSC2 inactivation, mice will be injected with TX neonatally. This will 
allow for precise examination and exploration of in vivo OB GC development to 
model defects. This Tsc2NSC-/- model will allow for novel insights into mechanisms 
that result in the TSC/mTORopathy phenotype.  
Although this model will serve as a powerful tool to study TSC, there are 
limitations relying solely on TX-CreERT2 mediated recombination to study neuron 
development TSC. We lack the ability to birthdate recombined cells labeled from 
neonatal TX administration, and there is a wide range of age heterogeneity in the 
OB due to ongoing GC neurogenesis. Since certain analysis depend on the age of 
the GCs, we can utilize the previously described electroporation technique from 
Chapters I-III to neonatally electroporate CAG-Cre and CAG-GFP DNA plasmids 
into the LV to target neuron producing NSCs. This method will also result in Tsc2 
excision and inactivation, while also transiently labelling a subset of cells with GFP. 
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We can then accurately analyze GCs with similar birthdates as the GFP plasmid 
dilutes out. Previous studies have successfully validated electroporations on Tsc1 
knockout mice, and our laboratory has previously published using the 
electroporation technique (20,42,48,51). Electroporations also achieve Tsc1/2 
inactivation in a more similar manner to inactivation exhibited in TSC patients, with 
a small subset of NSC/progenitors undergoing Tsc1/2 inactivation and giving rise 
to cells that inherit those mutations.  
The dual approaches of using a TX-inducible Nestin-CreERT2 mouse colony 
or introducing CAG-Cre via plasmid electroporation to induce Tsc2 inactivation in 
Tsc2fl/fl mice allows for examination of both global and localized effects of Tsc2 
deletion during neuron development. The experiments presented here validate the 
Tsc2NSC-/- mouse model using both strategies of Tsc2 excision and explore Tsc2 
null OB GC defects.  
 
Methods 
Slice preparation and immunohistochemistry  
Performed as described in chapter I using primary antibody pS6 (rabbit anti-
pS6; 1:1000; Cell Signaling Technology; Ser 240/244, 61H9, #4838). Images were 
acquired on a spectral confocal microscope (Leica SPE) with a 20× dry objective 




20× images were uploaded and analyzed using Fiji (ImageJ 1.5g). Sholl, 
soma size, and cell # were performed as described previously. 
 
Tamoxifen Injections 
Newborn pups were injected intraperitoneally with 50 µg/g TX, once at P0 
and once at P1, and sacrificed at indicated ages. Mice were routinely monitored 
for adverse effects.  
 
Genotyping PCR 
DNA samples were incubated in 75 μL 50 mM NaOH buffer at 50 °C for 90-
120 minutes. Following incubation, an equal volume of 100 mM Tris-HCl was 
added to samples. DNA concentration was calculated using a nanospectrometer. 
Samples were stored at −20 °C, and PCR was performed using platinum TAQ 
following manufacturer instructions (Thermofisher Scientific; 10966018). 
 
Neonatal electroporation  
Electroporations were performed as previously described in chapter III 







The TSC-mTOR pathway. 
The TSC1/2 (Harmartin-Tuberin) complex reduces mTORC1 activity in 
response to starvation signals that activate AMPK, which then phosphorylates and 
activates TSC1/2. TSC1/2 then inhibits the mTOR activator Rheb. When growth 
signals are present, TSC1/2 is inactive and Rheb activates mTORC1 at the 
lysosome (Fig. 4.1A). Inactivating mutations in TSC1/2 lead to unchecked mTOR 







Figure 4.1 The TSC-mTOR pathway. A. Canonical TSC-
mTOR pathway. B. TSC-mTOR pathway following TSC1/2 
inactivation. 
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Tsc2fl/fl tdTOMATOMut/Mut Nestin-CreERT2 mouse colony generation. 
Tsc2fl/fl mice were first crossed with Nestin-CreERT2 × tdTOMATOMut/Mut 
mice and crossed into homozygosity (Fig. 4.2A,B). All three transgenes were 
successfully incorporated in the expected mendelian ratios and validated by PCR 
(Fig. 4.2B). As described previously, NSCs produce progenitor cells that migrate 
through the RMS into the OB, where they then mature into functional GCs (Fig. 
4.2C). TX injection was administered two times neonatally, which resulted in robust 
recombination by P30 as demonstrated by red NSCs in the SVZ as well as red 
neurons in the OB (Fig. 4.2D-E). Recombined cell types were confirmed by the 
neuron marker NeuN, the NSC marker nestin, and the NSC/astrocyte marker 
GFAP. This confirms the incorporated transgenes are working correctly, with TX 
injection resulting in predictable patterning of recombination in nestin positive 
NSCs and the neuron progeny. 
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 Figure 4.2 Tsc2fl/fl tdTOMATOMut/Mut Nestin-CreERT2 mouse 
colony generation. A. Image of Tsc2NSC-/- mouse. B. PCR 
validation of indicated genotypes. C. Schematic diagram of a P30 
sagittal mouse brain demonstrating the migration pattern from the 
LV to the OB through the RMS. D. P30 tdTOMATO positive NeuN 
positive OB GCs following neonatal TX injections with NeuN 
(green) IHC. E. P30 tdTOMATO positive neural stem cells in the 
SVZ with nestin (green) and GFAP (blue) IHC. 
IHC=Immunohistochemistry. LV=Lateral Ventricle. OB=Olfactory 
bulb. RMS=Rostral Migratory Stream. GCL=Granule cell layer. 
EPL=External plexiform layer. SVZ=Subventricular zone. 
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mTORC1 activity upregulation in Tsc2 null OB GCs. 
Next, we wanted to confirm that mTORC1 activity was upregulated following 
Tsc2 removal. As demonstrated in Chapter III, neuron development involves 
changes in pS6 levels depending on the stage of growth. Additionally, GCs are 
continuously being produced throughout neonatal development. To compare 
mTORC1 activity more accurately between conditions, we shifted from TX injection 
to CAG-Cre and CAG-GFP neonatal electroporation of Tsc2fl/fl mice to study TSC2 
excision in OB GCs (Fig. 4.3A,B). Electroporations allowed us to examine GFP 
and tdTOMATO co-labeled GCs only, which successfully underwent Cre mediated 
recombination (red) and share a similar birthdate (green). Controls were littermates 
electroporated with an empty vector plasmid instead of Cre, thereby leaving the 
Tsc2 gene fully functional. Cre electroporations also result in many neighboring 
nonelectroporated GCs that have full Tsc2 functionality. This allows for another 
built in control where we can compare IHC intensity of Tsc2 null GCs with 
surrounding nonelectroporated cells. To examine mTORC1 levels, we performed 
pS6 Ser240/244 IHC at P14 and P30. pS6 was ~45% higher in Tsc2 null neurons 
at P14 compared to nonelectroporated controls (P<0.0001) (Fig. 4.3C-E). 
Interestingly, by P30 the pS6 expression increase in Tsc2 null GCs decreased to 
just ~7% compared to both nonelectroporated controls and GFP empty vector 







Figure 4.3 mTORC1 activity upregulation in Tsc2 null OB GCs. A. 
P14 tdTOMATO expression in the OB 14 days following neonatal 
Cre and GFP electroporations. B. P14 GCs in the GCL 
demonstrating plasmid GFP expression, tdTOMATO, and pS6 IHC. 
C-E. PS6 upregulation in OB GCs by P14 following Tsc2 removal. 
Arrows indicating upregulated pS6 in recombined GCs (P14 Control, 
N=4, n=82; P14 +Cre N=4, n=82). F. P30 pS6 intensity analysis (P30 
Control, N=4, n=41; P30 Tsc2fl/fl, N=4, n=34). 
IHC=Immunohistochemistry. GC(L)=Granule Cell (Layer). *=P<0.05. 
****=P<0.0001.  
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Morphological changes in Tsc2 null GCs. 
To assess the effect of Tsc2 inactivation on developing GCs, I next 
performed morphological analysis at P30 following neonatal electroporation of 
GFP and Cre into Tsc2fl/fl mice (Fig. 4.4A,B). Littermate controls were 
electroporated with an empty vector plasmid in place of Cre. Consistent with what 
was expected based on previous studies, P30 Tsc2 null GC soma size increased 
by ~25% (P<0.0001), and basal dendrite complexity increased by ~71% within 50 
microns of the soma (P<0.0001) (Fig. 4.4C,D). To confirm this was not a 
nonspecific Cre plasmid effect, the experiment was repeated using Cre 
electroporated Tsc2fl/wt mice as a control. Tsc2fl/wt GCs still have one functional 
allele following Cre electroporation, mitigating any defects. Consistent with our 
previous finding, Cre electroporated Tsc2fl/fl GCs underwent a 30% increase in 
soma size compared to Cre electroporated Tsc2fl/wt GCs (P<0.0001) (Fig. 4.4E). 
Taken together, TSC2 inactivation in Nestin positive cells during brain 
development recapitulates many major hallmarks of patients, including 
upregulated mTOR activity and altered neuron development. Both TX and Cre 
electroporated methods of Tsc2 excision were validated. These findings set the 
foundation in which future work using this colony will allow for robust investigation 




Figure 4.4 Morphological changes in Tsc2 null GCs. A. Representative 
image of a P30 control empty vector and GFP electroporated OB GC. B. 
Representative image of a P30 Cre and GFP electroporated OB GC. C. 
P30 soma size analysis (P30 Control, N=4, n=207; P30 +Cre, N=4, n=116). 
D. P30 Sholl analysis (P30 Control, N=3, n=23; P30 +Cre, N=4, n=30). E. 
P21 soma size analysis comparing Cre electroporated Tsc2fl/wt mice versus 







The data presented here provides evidence that the generated Tsc2NSC-
/- mouse line is an excellent model to study both neuron development and TSC 
associated brain defects. This Tsc2NSC-/- model faithfully recapitulates key 
hallmarks found in other TSC mouse models (42,133–141). Our results are also 
consistent with previous studies, which demonstrate that mTORC1 upregulation 
via Rheb overexpression results in neuron cytomegaly, dendrite hypertrophy, and 
ectopic migration (20,30). 
We found that changes in pS6 expression were more pronounced at P14 
than P30 in Tsc2 null GCs. The fact that Tsc2 inactivation appears to upregulate 
mTORC1 activity more robustly at earlier stages of neuron development indicates 
that immature neurons/neuroblasts may be more sensitive to Tsc2 alterations. A 
previous study investigating Tsc1 inactivation in NSCs/ astrocytes in mice did not 
find changes in radial glia proliferation or cell number; however, neurons exhibited 
an enlarged soma, upregulated mTOR activity, and ectopic migration (140). Taken 
together, this suggests that the neuroblast/immature neuron stage of neurogenesis 
is a particularly critical window in which altered mTOR activity is detrimental.   
            Other studies have focused on the effect of Tsc1 inactivation in post-mitotic 
cortical neurons using Camk2a-Cre Tsc1 mice, which exhibit seizure activity by 5 
weeks of age (139). The authors of the study postulated that the observed 
hyperexcitability resulted from increased mTOR-dependent autophagy (139). They 
found increased P62 and pUlk1 Ser757 expression in various brain regions 
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of Tsc1 transgenic mice. P62 is an autophagosome cargo protein that 
accumulates if autophagic processes are low (147). pUlk1 Ser757 is an mTORC1 
substrate and results in Ulk1 inhibition (69). Therefore, TSC1/2 inactivation may 
affect neuron development by decreasing autophagy. This in turn would disrupt 
synaptic pruning—a period of removal and refinement of synaptic connections 
following vast neuron outgrowth (43,148,149). Another study utilized Synapsin-Cre 
Tsc1 transgenic mice to excise Tsc1 in neurons and found similar issues such as 
decreased survival and seizures (137). Taken together, Tsc1/2 inactivating 
mutations is detrimental to brain development and function in multiple cell types. 
Future experiments using this Tsc2fl/fl colony should include performing in 
utero electroporations of Cre plasmid to examine if cortical tubers form. Excision 
of Tsc2 mediated by the TX-inducible CreERT2 recombinase is too widespread and 
ineffective at inducing the formation of cortical tubers and/or nodules in the LV that 
typically result from Tsc1/2 inactivation in a subset of cells. Methods utilizing 
plasmid introduction by neonatal or in utero electroporation to 
remove Tsc1/2 more faithfully recapitulate cellular heterogeneity and mosaic 
patterning that occurs in TSC patients. In utero electroporations involve the 
injection of plasmid DNA into the LV when cortical neurons are being generated. 
The nature of in utero electroporation facilitates inactivation in a subset of cells 
much like what occurs in patients with cortical tubers. As TSC patients start with 
one working allele, somatic mosaicism develops with a second hit mutation 
occurring in a progenitor/NSC, leading to a subset of cells with biallelic TSC1/2 
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inactivation (150,151). Thus, Cre-mediated recombination introduced via 
electroporation more accurately models TSC1/2 recombination in patients 
compared to TX- CreERT2 mediated Tsc1/2 inactivation in mice. Finally, seizure 
activity should be monitored following neonatal and in utero electroporations. 
Global recombination of Tsc2 by Nestin-CreERT2 should be used as a 
supplementary technique to examine the brain defects in Tsc2NSC-/- mice. The use 
of two different methods of Cre mediated Tsc2 inactivation in this colony provides 
the framework for the future expansion in the existing body of knowledge for 

















Summary, Significance, and Future Directions 
The findings presented here highlight the intricacies of neuron development 
and how alterations in neuronal machinery result in neurodevelopmental defects. 
Through advanced in vivo genetic manipulation using in utero and neonatal 
electroporations, I provide mechanistic insight into how Slc7a5 and Ulk1 play a role 
in neuron development and survival (51). Alternation to either Slc7a5 or Ulk1 
expression was found to result in defective neuron development. Both were found 
to be directly involved with mTORC1 during development, with Slc7a5 regulating 
mTORC1 activity in OB GCs and Ulk1 being phosphorylated by mTORC1 in 
cortical pyramidal neurons. 
The potential clinical significance of SLC7A5 is highlighted in the fact that 
Slc7a5 rescued Rheb overexpression mediated morphological changes such as 
increased mTORC1 activity and dendrite hypertrophy (51). This demonstrates 
SLC7A5 may be able to reduce mTOR activity and rescue neuron morphology in 
TSC patients. The activation of mTORC1 relies on the presence of amino acids 
and growth factors. Growth factors induce mTORC1 activity through the inhibition 
of TSC1/2, while amino acids activate mTORC1 through an independent Sestrin2-
Rag GTPase pathway (94,152). Thus, while TSC1/2 null cells are no longer 
sensitive to the absence or presence of growth factors, perhaps mTORC1 
upregulation can be controlled through the reduction of SLC7A5 transport of amino 
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acids into the cell. Interestingly, an abnormal cell type found in the cortex of TSC 
patients, known as balloon cells, have upregulated SLC7A5 expression (55). As 
SLC7A5 mutations have also been found to cause autism spectrum disorder, the 
continued investigation of how SLC7A5 is involved with neuron development is 
essential to move the field forward, with the hope of uncovering more effective 
therapeutic strategies and targets (53). 
Additionally, altered autophagy has been found in TSC mouse models and 
autism spectrum disorder patients, highlighting the potential importance of Ulk1 
regulation in neuron development (43,139). Interestingly, studies demonstrate that 
autophagy is required to support upregulated mTOR in Tsc1/2 null cells, and that 
inactivation of the autophagy gene Fip200 rescued the TSC phenotype (153). Our 
data suggests that Ulk1 is robustly inhibited by mTORC1 in developing neurons. 
This would suggest that ULK1 is likely involved with autophagic dysregulation in 
TSC patients. Further work must be conducted to explore the link between 
mTORC1 and ULK1 in patients with mutations resulting in increased mTORC1 
activity. If the role of autophagy and ULK1 can be confirmed, it can potentially be 
exploited as another potential therapeutic target.   
The continued exploration of neuron development regulators and their role 
in neurodevelopmental disorders is of vital importance for the continued expansion 
of our body of knowledge. For the more we uncover about the inner workings of 
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